{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:44:57Z","timestamp":1793285097111,"version":"4.5.0"},"reference-count":510,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011002","name":"National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","award":["82473348"],"award-info":[{"award-number":["82473348"]}],"id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02769-3","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:01:11Z","timestamp":1784674871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics"],"prefix":"10.1038","volume":"11","author":[{"given":"Leiguang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"2769_CR2","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.ctrv.2022.102383","volume":"106","author":"H Fritah","year":"2022","unstructured":"Fritah, H., Rovelli, R., Chiang, C. L. & Kandalaft, L. E. The current clinical landscape of personalized cancer vaccines. Cancer Treat. Rev. 106, 102383 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"2769_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/1097-0142(197711)40:5<2091::AID-CNCR2820400517>3.0.CO;2-H","volume":"40","author":"JF Laucius","year":"1977","unstructured":"Laucius, J. F., Bodurtha, A. J., Mastrangelo, J. M. & Bellet, R. E. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer 40, 2091\u20132093 (1977).","journal-title":"Cancer"},{"key":"2769_CR4","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1073\/pnas.85.7.2274","volume":"85","author":"E De Plaen","year":"1988","unstructured":"De Plaen, E. et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc. Natl. Acad. Sci. USA 85, 2274\u20132278 (1988).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2769_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/clin.1997.4419","volume":"85","author":"T Sato","year":"1997","unstructured":"Sato, T. et al. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clin. Immunol. Immunopathol. 85, 265\u2013272 (1997).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"2769_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2769_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"2769_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"2769_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"2769_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"2769_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"2769_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"2769_CR13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"2769_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2183814","volume":"30","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy. Drug Deliv. 30, 2183814 (2023).","journal-title":"Drug Deliv."},{"key":"2769_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1357217","volume":"15","author":"A Kumar","year":"2024","unstructured":"Kumar, A. et al. Personalized cancer vaccine design using AI-powered technologies. Front Immunol. 15, 1357217 (2024).","journal-title":"Front Immunol."},{"key":"2769_CR16","doi-asserted-by":"crossref","unstructured":"Yang, M. et al. Tumor cell membrane-based vaccines: a potential boost for cancer immunotherapy. Exploration 4, 20230171 (2024).","DOI":"10.1002\/EXP.20230171"},{"key":"2769_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.medj.2024.03.012","volume":"5","author":"G Zhao","year":"2024","unstructured":"Zhao, G., Wang, S., Nie, G. & Li, N. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment. Med 5, 660\u2013688 (2024).","journal-title":"Med"},{"key":"2769_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"2769_CR19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik, A. A., Hwu, P., Mule, J. J. & Pilon-Thomas, S. Tumor-infiltrating lymphocytes: a new hope. Cancer Cell 42, 1315\u20131318 (2024).","journal-title":"Cancer Cell"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759\u20131776 (2021).","journal-title":"Br. J. Cancer"},{"key":"2769_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh, C. S. et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol. Ther. 29, 555\u2013570 (2021).","journal-title":"Mol. Ther."},{"key":"2769_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","volume":"18","author":"J Xin Yu","year":"2019","unstructured":"Xin Yu, J., Hubbard-Lucey, V. M. & Tang, J. Immuno-oncology drug development goes global. Nat. Rev. Drug Discov. 18, 899\u2013900 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2769_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2769_CR24","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.7150\/thno.24387","volume":"8","author":"Y Chu","year":"2018","unstructured":"Chu, Y., Liu, Q., Wei, J. & Liu, B. Personalized cancer neoantigen vaccines come of age. Theranostics 8, 4238\u20134246 (2018).","journal-title":"Theranostics"},{"key":"2769_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2018.12.001","volume":"73","author":"R Tokunaga","year":"2019","unstructured":"Tokunaga, R. et al. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat. Rev. 73, 10\u201319 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"2769_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong, Y., Lin, Y., Wei, T. & Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv. Mater. 35, e2303261 (2023).","journal-title":"Adv. Mater."},{"key":"2769_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","volume":"32","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 32, 693\u2013710 (2014).","journal-title":"Biotechnol. Adv."},{"key":"2769_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tibtech.2019.11.001","volume":"38","author":"YC Ou","year":"2020","unstructured":"Ou, Y. C., Wen, X. & Bardhan, R. Cancer immunoimaging with smart nanoparticles. Trends Biotechnol. 38, 388\u2013403 (2020).","journal-title":"Trends Biotechnol."},{"key":"2769_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4049\/jimmunol.2300038","volume":"212","author":"MD Castro Eiro","year":"2024","unstructured":"Castro Eiro, M. D. et al. TLR9 plus STING agonist adjuvant combination induces potent neopeptide T cell immunity and improves immune checkpoint blockade efficacy in a tumor model. J. Immunol. 212, 455\u2013465 (2024).","journal-title":"J. Immunol."},{"key":"2769_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202401631","volume":"20","author":"N Desai","year":"2024","unstructured":"Desai, N. et al. Cancer nanovaccines: nanomaterials and clinical perspectives. Small 20, e2401631 (2024).","journal-title":"Small"},{"key":"2769_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53937-4","volume":"15","author":"Q Feng","year":"2024","unstructured":"Feng, Q. et al. Rationally designed multimeric nanovaccines using icosahedral DNA origami for display of SARS-CoV-2 receptor binding domain. Nat. Commun. 15, 9581 (2024).","journal-title":"Nat. Commun."},{"key":"2769_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202109984","volume":"34","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine. Adv. Mater. 34, e2109984 (2022).","journal-title":"Adv. Mater."},{"key":"2769_CR33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jconrel.2023.02.015","volume":"355","author":"Y Yi","year":"2023","unstructured":"Yi, Y. et al. Vaccine-like nanomedicine for cancer immunotherapy. J. Control Release 355, 760\u2013778 (2023).","journal-title":"J. Control Release"},{"key":"2769_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901255","volume":"32","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Biomimetic nanotechnology toward personalized vaccines. Adv. Mater. 32, e1901255 (2020).","journal-title":"Adv. Mater."},{"key":"2769_CR35","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.20892\/j.issn.2095-3941.2022.0452","volume":"19","author":"X Gao","year":"2022","unstructured":"Gao, X., Feng, Q., Wang, J. & Zhao, X. Bacterial outer membrane vesicle-based cancer nanovaccines. Cancer Biol. Med. 19, 1290\u20131300 (2022).","journal-title":"Cancer Biol. Med."},{"key":"2769_CR36","doi-asserted-by":"publisher","first-page":"113889","DOI":"10.1016\/j.addr.2021.113889","volume":"176","author":"G Liu","year":"2021","unstructured":"Liu, G., Zhu, M., Zhao, X. & Nie, G. Nanotechnology-empowered vaccine delivery for enhancing CD8(+) T cells-mediated cellular immunity. Adv. Drug Deliv. Rev. 176, 113889 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2769_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1590","volume":"12","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12, e1590 (2020).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"2769_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).","journal-title":"Mol. Cancer"},{"key":"2769_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2018.10.008","volume":"292","author":"R Zhang","year":"2018","unstructured":"Zhang, R., Billingsley, M. M. & Mitchell, M. J. Biomaterials for vaccine-based cancer immunotherapy. J. Control Release 292, 256\u2013276 (2018).","journal-title":"J. Control Release"},{"key":"2769_CR40","doi-asserted-by":"publisher","first-page":"113927","DOI":"10.1016\/j.addr.2021.113927","volume":"177","author":"T Ye","year":"2021","unstructured":"Ye, T., Li, F., Ma, G. & Wei, W. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Adv. Drug Deliv. Rev. 177, 113927 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2769_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121297","volume":"280","author":"DI Viswanath","year":"2022","unstructured":"Viswanath, D. I. et al. Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. Biomaterials 280, 121297 (2022).","journal-title":"Biomaterials"},{"key":"2769_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203921","volume":"9","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. Rational nanomedicine design enhances clinically physical treatment-inspired or combined immunotherapy. Adv. Sci. 9, e2203921 (2022).","journal-title":"Adv. Sci."},{"key":"2769_CR43","doi-asserted-by":"publisher","first-page":"18889","DOI":"10.1021\/acsnano.5c06380","volume":"19","author":"CA Mirkin","year":"2025","unstructured":"Mirkin, C. A. et al. Blueprints for better drugs: the structural revolution in nanomedicine. ACS Nano 19, 18889\u201318901 (2025).","journal-title":"ACS Nano"},{"key":"2769_CR44","doi-asserted-by":"crossref","unstructured":"Sun, Q., Zhou, Z., Qiu, N. & Shen, Y. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv. Mater. 29, e1606628 (2017).","DOI":"10.1002\/adma.201606628"},{"key":"2769_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387\u20131390 (2015).","journal-title":"Science"},{"key":"2769_CR46","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi, N., Jaffee, E. M. & Yarchoan, M. Recent advances in therapeutic cancer vaccines. Nat. Rev. Cancer 25, 517\u2013533 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR47","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"2769_CR48","first-page":"100860","volume":"42","author":"D Singh","year":"2024","unstructured":"Singh, D. et al. Personalized medicine: an alternative for cancer treatment. Cancer Treat. Res. Commun. 42, 100860 (2024).","journal-title":"Cancer Treat. Res. Commun."},{"key":"2769_CR49","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"2769_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02817-y","volume":"42","author":"Rituraj","year":"2025","unstructured":"Rituraj et al. Precision oncology: transforming cancer care through personalized medicine. Med. Oncol. 42, 246 (2025).","journal-title":"Med. Oncol."},{"key":"2769_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2769_CR52","doi-asserted-by":"crossref","unstructured":"Liu, C. C. et al. Tumour-associated antigens and their anti-cancer applications. Eur. J. Cancer Care 26, e12446 (2017).","DOI":"10.1111\/ecc.12446"},{"key":"2769_CR53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"2769_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","volume":"406","author":"O Pail","year":"2025","unstructured":"Pail, O. et al. Cancer vaccines and the future of immunotherapy. Lancet 406, 189\u2013202 (2025).","journal-title":"Lancet"},{"key":"2769_CR55","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/qjmed\/hcad089","volume":"116","author":"G Zhao","year":"2023","unstructured":"Zhao, G. et al. Membrane-based cancer nanovaccines: the time is now. QJM 116, 621\u2013624 (2023).","journal-title":"QJM"},{"key":"2769_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."},{"key":"2769_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng, M. et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol. Cancer 18, 128 (2019).","journal-title":"Mol. Cancer"},{"key":"2769_CR58","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1110\/ps.0239403","volume":"12","author":"M Nielsen","year":"2003","unstructured":"Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007\u20131017 (2003).","journal-title":"Protein Sci."},{"key":"2769_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"2769_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR61","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman, A. H. et al. Targeting public neoantigens for cancer immunotherapy. Nat. Cancer 2, 487\u2013497 (2021).","journal-title":"Nat. Cancer"},{"key":"2769_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","volume":"91","author":"T Li","year":"2023","unstructured":"Li, T. et al. Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction. Semin. Cancer Biol. 91, 50\u201369 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"2769_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","volume":"84","author":"S Pounraj","year":"2024","unstructured":"Pounraj, S. et al. Targeting tumor heterogeneity with neoantigen-based cancer vaccines. Cancer Res. 84, 353\u2013363 (2024).","journal-title":"Cancer Res."},{"key":"2769_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F. et al. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2769_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"2769_CR66","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.7150\/ijbs.76281","volume":"18","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Int. J. Biol. Sci. 18, 5607\u20135623 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2769_CR67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14760584.2022.2012456","volume":"21","author":"G Richard","year":"2022","unstructured":"Richard, G. et al. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev. Vaccines 21, 173\u2013184 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR68","doi-asserted-by":"crossref","unstructured":"Bulik-Sullivan, B. et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat. Biotechnol. (2018).","DOI":"10.1038\/nbt.4313"},{"key":"2769_CR69","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","volume":"37","author":"B Chen","year":"2019","unstructured":"Chen, B. et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat. Biotechnol. 37, 1332\u20131343 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2769_CR70","doi-asserted-by":"publisher","first-page":"bbae302","DOI":"10.1093\/bib\/bbae302","volume":"25","author":"Q Yang","year":"2024","unstructured":"Yang, Q. et al. HLAIImaster: a deep learning method with adaptive domain knowledge predicts HLA II neoepitope immunogenic responses. Brief. Bioinform. 25, bbae302 (2024).","journal-title":"Brief. Bioinform."},{"key":"2769_CR71","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO Guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2769_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding, Z. et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct. Target. Ther. 6, 26 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2769_CR73","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ccell.2018.03.026","volume":"33","author":"X Peng","year":"2018","unstructured":"Peng, X. et al. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell 33, 817\u2013828.e817 (2018).","journal-title":"Cancer Cell"},{"key":"2769_CR74","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.aad2791","volume":"351","author":"T Delong","year":"2016","unstructured":"Delong, T. et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351, 711\u2013714 (2016).","journal-title":"Science"},{"key":"2769_CR75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","volume":"25","author":"CY Moon","year":"2025","unstructured":"Moon, C. Y. et al. Dendritic cell maturation in cancer. Nat. Rev. Cancer 25, 225\u2013248 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465\u2013478 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR77","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR78","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","volume":"129","author":"A Perez-Banos","year":"2023","unstructured":"Perez-Banos, A. et al. Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. Br. J. Cancer 129, 572\u2013585 (2023).","journal-title":"Br. J. Cancer"},{"key":"2769_CR79","doi-asserted-by":"publisher","first-page":"e2300121","DOI":"10.1002\/advs.202300121","volume":"10","author":"L Diao","year":"2023","unstructured":"Diao, L. & Liu, M. Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell. Adv. Sci. 10, e2300121 (2023).","journal-title":"Adv. Sci."},{"key":"2769_CR80","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","volume":"169","author":"SP Lau","year":"2022","unstructured":"Lau, S. P. et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study. Eur. J. Cancer 169, 20\u201331 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2769_CR81","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","volume":"22","author":"CL Chiang","year":"2010","unstructured":"Chiang, C. L., Benencia, F. & Coukos, G. Whole tumor antigen vaccines. Semin. Immunol. 22, 132\u2013143 (2010).","journal-title":"Semin. Immunol."},{"key":"2769_CR82","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","volume":"10","author":"FE Gonzalez","year":"2014","unstructured":"Gonzalez, F. E. et al. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum. Vaccin. Immunother. 10, 3261\u20133269 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2769_CR83","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner, A. & Ruffell, B. Dendritic cells and cancer immunity. Trends Immunol. 37, 855\u2013865 (2016).","journal-title":"Trends Immunol."},{"key":"2769_CR84","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1172\/JCI31205","volume":"117","author":"E Gilboa","year":"2007","unstructured":"Gilboa, E. DC-based cancer vaccines. J. Clin. Invest. 117, 1195\u20131203 (2007).","journal-title":"J. Clin. Invest."},{"key":"2769_CR85","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos, P. M. & Butterfield, L. H. Dendritic cell-based cancer vaccines. J. Immunol. 200, 443\u2013449 (2018).","journal-title":"J. Immunol."},{"key":"2769_CR86","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1586\/1744666X.2015.987663","volume":"11","author":"N Mody","year":"2015","unstructured":"Mody, N. et al. Dendritic cell-based vaccine research against cancer. Expert Rev. Clin. Immunol. 11, 213\u2013232 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2769_CR87","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coi.2014.01.005","volume":"27","author":"KJ Radford","year":"2014","unstructured":"Radford, K. J., Tullett, K. M. & Lahoud, M. H. Dendritic cells and cancer immunotherapy. Curr. Opin. Immunol. 27, 26\u201332 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"2769_CR88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.smim.2011.01.003","volume":"23","author":"L Apetoh","year":"2011","unstructured":"Apetoh, L. et al. Harnessing dendritic cells in cancer. Semin. Immunol. 23, 42\u201349 (2011).","journal-title":"Semin. Immunol."},{"key":"2769_CR89","doi-asserted-by":"publisher","first-page":"125849","DOI":"10.1016\/j.ijpharm.2025.125849","volume":"681","author":"AR Hilles","year":"2025","unstructured":"Hilles, A. R. et al. Cell membrane vaccine delivery system: a review of the recent advances against breast cancer. Int J. Pharm. 681, 125849 (2025).","journal-title":"Int J. Pharm."},{"key":"2769_CR90","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/pharmaceutics16010022","volume":"16","author":"X An","year":"2023","unstructured":"An, X., Zeng, Y., Liu, C. & Liu, G. Cellular-membrane-derived vesicles for cancer immunotherapy. Pharmaceutics 16, 22 (2023).","journal-title":"Pharmaceutics"},{"key":"2769_CR91","doi-asserted-by":"publisher","first-page":"216989","DOI":"10.1016\/j.canlet.2024.216989","volume":"595","author":"G Zhao","year":"2024","unstructured":"Zhao, G. et al. Exosome-based anticancer vaccines: From Bench to bedside. Cancer Lett. 595, 216989 (2024).","journal-title":"Cancer Lett."},{"key":"2769_CR92","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1016\/j.apsb.2022.02.023","volume":"12","author":"Y Zeng","year":"2022","unstructured":"Zeng, Y. et al. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm. Sin. B 12, 3233\u20133254 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2769_CR93","doi-asserted-by":"publisher","first-page":"973601","DOI":"10.3389\/fimmu.2022.973601","volume":"13","author":"Q Jiang","year":"2022","unstructured":"Jiang, Q. et al. Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: a review of current developments. Front. Immunol. 13, 973601 (2022).","journal-title":"Front. Immunol."},{"key":"2769_CR94","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"2769_CR95","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/dna.1993.12.771","volume":"12","author":"MA Yankauckas","year":"1993","unstructured":"Yankauckas, M. A. et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol. 12, 771\u2013776 (1993).","journal-title":"DNA Cell Biol."},{"key":"2769_CR96","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","volume":"38","author":"A Lopes","year":"2019","unstructured":"Lopes, A., Vandermeulen, G. & Preat, V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J. Exp. Clin. Cancer Res 38, 146 (2019).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"2769_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02060-3","volume":"40","author":"A Pandya","year":"2023","unstructured":"Pandya, A. et al. The future of cancer immunotherapy: DNA vaccines leading the way. Med. Oncol. 40, 200 (2023).","journal-title":"Med. Oncol."},{"key":"2769_CR98","doi-asserted-by":"publisher","first-page":"1498431","DOI":"10.3389\/fimmu.2024.1498431","volume":"15","author":"A Shariati","year":"2024","unstructured":"Shariati, A. et al. DNA vaccines as promising immuno-therapeutics against cancer: a new insight. Front. Immunol. 15, 1498431 (2024).","journal-title":"Front. Immunol."},{"key":"2769_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","volume":"165","author":"A Tiptiri-Kourpeti","year":"2016","unstructured":"Tiptiri-Kourpeti, A., Spyridopoulou, K., Pappa, A. & Chlichlia, K. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol. Ther. 165, 32\u201349 (2016).","journal-title":"Pharmacol. Ther."},{"key":"2769_CR100","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.4161\/hv.22345","volume":"8","author":"AA Herrada","year":"2012","unstructured":"Herrada, A. A. et al. Harnessing DNA-induced immune responses for improving cancer vaccines. Hum. Vaccin. Immunother. 8, 1682\u20131693 (2012).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2769_CR101","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang, M. et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13, 81 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2769_CR102","doi-asserted-by":"publisher","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","volume":"28","author":"L Li","year":"2017","unstructured":"Li, L., Goedegebuure, S. P. & Gillanders, W. E. Preclinical and clinical development of neoantigen vaccines. Ann. Oncol. 28, xii11\u2013xii17 (2017).","journal-title":"Ann. Oncol."},{"key":"2769_CR103","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-018-0751-1","volume":"37","author":"L Aurisicchio","year":"2018","unstructured":"Aurisicchio, L., Pallocca, M., Ciliberto, G. & Palombo, F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J. Exp. Clin. Cancer Res. 37, 86 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2769_CR104","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","volume":"22","author":"A Desrichard","year":"2016","unstructured":"Desrichard, A., Snyder, A. & Chan, T. A. Cancer neoantigens and applications for immunotherapy. Clin. Cancer Res. 22, 807\u2013812 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2769_CR105","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"2769_CR106","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2326-6066.CIR-18-0283","volume":"7","author":"EK Duperret","year":"2019","unstructured":"Duperret, E. K. et al. A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8(+) T-cell responses, impacting tumor challenge. Cancer Immunol. Res. 7, 174\u2013182 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2769_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 16, 131 (2024).","journal-title":"Genome Med."},{"key":"2769_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02211-8","volume":"24","author":"D Chai","year":"2025","unstructured":"Chai, D. et al. Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity. Mol. Cancer 24, 12 (2025).","journal-title":"Mol. Cancer"},{"key":"2769_CR109","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1021\/acs.nanolett.5b00570","volume":"15","author":"Q Hu","year":"2015","unstructured":"Hu, Q. et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 15, 2732\u20132739 (2015).","journal-title":"Nano Lett."},{"key":"2769_CR110","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10529-023-03383-x","volume":"45","author":"M Danaeifar","year":"2023","unstructured":"Danaeifar, M. et al. Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: a review. Biotechnol. Lett. 45, 1053\u20131072 (2023).","journal-title":"Biotechnol. Lett."},{"key":"2769_CR111","doi-asserted-by":"publisher","first-page":"140558","DOI":"10.1016\/j.ijbiomac.2025.140558","volume":"302","author":"P Yaraghi","year":"2025","unstructured":"Yaraghi, P. et al. Nanoparticle-mediated enhancement of DNA Vaccines: Revolutionizing immunization strategies. Int. J. Biol. Macromol. 302, 140558 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"2769_CR112","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"D Hobernik","year":"2018","unstructured":"Hobernik, D. & Bros, M. DNA vaccines-how far from clinical use? Int. J. Mol. Sci. 19, 3605 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2769_CR113","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","volume":"109","author":"N Sobhani","year":"2022","unstructured":"Sobhani, N. et al. Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials. Cancer Treat. Rev. 109, 102429 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"2769_CR114","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","volume":"25","author":"Z Jahanafrooz","year":"2020","unstructured":"Jahanafrooz, Z. et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov. Today 25, 552\u2013560 (2020).","journal-title":"Drug Discov. Today"},{"key":"2769_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"2769_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. mRNA vaccine in cancer therapy: current advance and future outlook. Clin. Transl. Med. 13, e1384 (2023).","journal-title":"Clin. Transl. Med."},{"key":"2769_CR117","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR118","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489\u2013500 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR119","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen, C. L., Haanen, J. B., Met, O. & Svane, I. M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450\u2013e458 (2022).","journal-title":"Lancet Oncol."},{"key":"2769_CR120","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41392-025-02204-z","volume":"10","author":"E Schaeffeler","year":"2025","unstructured":"Schaeffeler, E., Walz, J. & Schwab, M. Personalized cancer vaccination is emerging: lessons learnt from renal cancer and challenges for broader application. Signal Transduct. Target. Ther. 10, 107 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2769_CR121","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14\u201320 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"2769_CR122","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2769_CR123","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon, E. et al. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat. Rev. Clin. Oncol. 20, 739\u2013754 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR124","doi-asserted-by":"publisher","first-page":"115190","DOI":"10.1016\/j.addr.2024.115190","volume":"206","author":"M Estape Senti","year":"2024","unstructured":"Estape Senti, M., Garcia Del Valle, L. & Schiffelers, R. M. mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond. Adv. Drug Deliv. Rev. 206, 115190 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2769_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko, A. V. et al. Clinical advances of mRNA vaccines for cancer immunotherapy. Med 6, 100562 (2025).","journal-title":"Med"},{"key":"2769_CR126","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2769_CR127","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204 (2024).","journal-title":"Lancet"},{"key":"2769_CR128","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2769_CR129","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","volume":"42","author":"P Guasp","year":"2024","unstructured":"Guasp, P., Reiche, C., Sethna, Z. & Balachandran, V. P. RNA vaccines for cancer: Principles to practice. Cancer Cell 42, 1163\u20131184 (2024).","journal-title":"Cancer Cell"},{"key":"2769_CR130","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J. et al. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2769_CR131","first-page":"2479","volume":"56","author":"X Hu","year":"1996","unstructured":"Hu, X. et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56, 2479\u20132483 (1996).","journal-title":"Cancer Res."},{"key":"2769_CR132","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ijc.11292","volume":"106","author":"E Jager","year":"2003","unstructured":"Jager, E., Jager, D. & Knuth, A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106, 817\u2013820 (2003).","journal-title":"Int. J. Cancer"},{"key":"2769_CR133","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12026-014-8505-4","volume":"58","author":"MS Khodadoust","year":"2014","unstructured":"Khodadoust, M. S. & Alizadeh, A. A. Tumor antigen discovery through translation of the cancer genome. Immunol. Res. 58, 292\u2013299 (2014).","journal-title":"Immunol. Res."},{"key":"2769_CR134","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.ccell.2021.11.005","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A., Parker, K. R. & Satpathy, A. T. Charting the tumor antigen maps drawn by single-cell genomics. Cancer Cell 39, 1553\u20131557 (2021).","journal-title":"Cancer Cell"},{"key":"2769_CR135","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/13543784.2021.1896702","volume":"30","author":"S Supabphol","year":"2021","unstructured":"Supabphol, S., Li, L., Goedegebuure, S. P. & Gillanders, W. E. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opin. Investig. Drugs 30, 529\u2013541 (2021).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2769_CR136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell 41, 15\u201340 (2023).","journal-title":"Cancer Cell"},{"key":"2769_CR137","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/molecules26020430","volume":"26","author":"V Apostolopoulos","year":"2021","unstructured":"Apostolopoulos, V. et al. A global review on short peptides: frontiers and perspectives. Molecules 26, 430 (2021).","journal-title":"Molecules"},{"key":"2769_CR138","doi-asserted-by":"publisher","first-page":"1210044","DOI":"10.3389\/fimmu.2023.1210044","volume":"14","author":"L Buonaguro","year":"2023","unstructured":"Buonaguro, L. & Tagliamonte, M. Peptide-based vaccine for cancer therapies. Front. Immunol. 14, 1210044 (2023).","journal-title":"Front. Immunol."},{"key":"2769_CR139","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4049\/jimmunol.154.1.247","volume":"154","author":"J Sidney","year":"1995","unstructured":"Sidney, J. et al. Several HLA alleles share overlapping peptide specificities. J. Immunol. 154, 247\u2013259 (1995).","journal-title":"J. Immunol."},{"key":"2769_CR140","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","volume":"160","author":"S Southwood","year":"1998","unstructured":"Southwood, S. et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363\u20133373 (1998).","journal-title":"J. Immunol."},{"key":"2769_CR141","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/eji.200737995","volume":"38","author":"MS Bijker","year":"2008","unstructured":"Bijker, M. S. et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38, 1033\u20131042 (2008).","journal-title":"Eur. J. Immunol."},{"key":"2769_CR142","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","volume":"20","author":"A Nelde","year":"2021","unstructured":"Nelde, A., Rammensee, H. G. & Walz, J. S. The peptide vaccine of the future. Mol. Cell Proteom. 20, 100022 (2021).","journal-title":"Mol. Cell Proteom."},{"key":"2769_CR143","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14760584.2019.1635461","volume":"18","author":"Y Nakahara","year":"2019","unstructured":"Nakahara, Y. et al. Prospects for a personalized peptide vaccine against lung cancer. Expert Rev. Vaccines 18, 703\u2013709 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR144","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/978-1-4939-3387-7_46","volume":"1403","author":"E Schneble","year":"2016","unstructured":"Schneble, E., Clifton, G. T., Hale, D. F. & Peoples, G. E. Peptide-based cancer vaccine strategies and clinical results. Methods Mol. Biol. 1403, 797\u2013817 (2016).","journal-title":"Methods Mol. Biol."},{"key":"2769_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13025","volume":"54","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Peptide-based therapeutic cancer vaccine: current trends in clinical application. Cell Prolif. 54, e13025 (2021).","journal-title":"Cell Prolif."},{"key":"2769_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-S12-S22","volume":"9","author":"HH Lin","year":"2008","unstructured":"Lin, H. H. et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinform. 9, S22 (2008).","journal-title":"BMC Bioinform."},{"key":"2769_CR147","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.3390\/ijms24109024","volume":"24","author":"I Malaina","year":"2023","unstructured":"Malaina, I. et al. Computational and experimental evaluation of the immune response of neoantigens for personalized vaccine design. Int. J. Mol. Sci. 24, 9024 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2769_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682103","volume":"12","author":"Q Hao","year":"2021","unstructured":"Hao, Q. et al. Improvement of neoantigen identification through convolution neural network. Front Immunol. 12, 682103 (2021).","journal-title":"Front Immunol."},{"key":"2769_CR149","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.3390\/ijms241612931","volume":"24","author":"NTT Nhan","year":"2023","unstructured":"Nhan, N. T. T., Yamada, T. & Yamada, K. H. Peptide-based agents for cancer treatment: current applications and future directions. Int. J. Mol. Sci. 24, 12931 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2769_CR150","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.2174\/0929867321666140205132936","volume":"21","author":"T Sasada","year":"2014","unstructured":"Sasada, T., Yamada, A., Noguchi, M. & Itoh, K. Personalized peptide vaccine for treatment of advanced cancer. Curr. Med. Chem. 21, 2332\u20132345 (2014).","journal-title":"Curr. Med. Chem."},{"key":"2769_CR151","doi-asserted-by":"publisher","first-page":"761820","DOI":"10.1155\/2015\/761820","volume":"2015","author":"YF Xiao","year":"2015","unstructured":"Xiao, Y. F. et al. Peptide-based treatment: a promising cancer therapy. J. Immunol. Res. 2015, 761820 (2015).","journal-title":"J. Immunol. Res."},{"key":"2769_CR152","doi-asserted-by":"publisher","first-page":"110721","DOI":"10.1016\/j.intimp.2023.110721","volume":"123","author":"F Zahedipour","year":"2023","unstructured":"Zahedipour, F., Jamialahmadi, K., Zamani, P. & Reza Jaafari, M. Improving the efficacy of peptide vaccines in cancer immunotherapy. Int. Immunopharmacol. 123, 110721 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2769_CR153","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/ph16070923","volume":"16","author":"ML Nordin","year":"2023","unstructured":"Nordin, M. L. et al. Peptide-based vaccine against breast cancer: recent advances and prospects. Pharmaceuticals 16, 923 (2023).","journal-title":"Pharmaceuticals"},{"key":"2769_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-3","volume":"10","author":"A Bolhassani","year":"2011","unstructured":"Bolhassani, A., Safaiyan, S. & Rafati, S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer 10, 3 (2011).","journal-title":"Mol. Cancer"},{"key":"2769_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101192","volume":"92","author":"L Buonaguro","year":"2023","unstructured":"Buonaguro, L. et al. Microorganisms-derived antigens for preventive anti-cancer vaccines. Mol. Asp. Med. 92, 101192 (2023).","journal-title":"Mol. Asp. Med."},{"key":"2769_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03512-6","volume":"20","author":"C Ragone","year":"2022","unstructured":"Ragone, C. et al. Molecular mimicry between tumor associated antigens and microbiota-derived epitopes. J. Transl. Med. 20, 316 (2022).","journal-title":"J. Transl. Med."},{"key":"2769_CR157","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/2326-6066.CIR-20-0814","volume":"9","author":"J Chiaro","year":"2021","unstructured":"Chiaro, J. et al. Viral molecular mimicry influences the antitumor immune response in murine and human melanoma. Cancer Immunol. Res. 9, 981\u2013993 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2769_CR158","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.nano.2018.09.004","volume":"15","author":"M Neek","year":"2019","unstructured":"Neek, M., Kim, T. I. & Wang, S. W. Protein-based nanoparticles in cancer vaccine development. Nanomedicine 15, 164\u2013174 (2019).","journal-title":"Nanomedicine"},{"key":"2769_CR159","doi-asserted-by":"publisher","first-page":"9749363","DOI":"10.1155\/2022\/9749363","volume":"2022","author":"N Abd-Aziz","year":"2022","unstructured":"Abd-Aziz, N. & Poh, C. L. Development of peptide-based vaccines for cancer. J. Oncol. 2022, 9749363 (2022).","journal-title":"J. Oncol."},{"key":"2769_CR160","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-4542-0_4","volume":"2926","author":"HM Maeng","year":"2025","unstructured":"Maeng, H. M. et al. Dendritic cell cancer vaccines: a focused review. Methods Mol. Biol. 2926, 51\u201356 (2025).","journal-title":"Methods Mol. Biol."},{"key":"2769_CR161","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.21873\/anticanres.17196","volume":"44","author":"T Kamigaki","year":"2024","unstructured":"Kamigaki, T. et al. Personalized dendritic-cell-based vaccines targeting cancer neoantigens. Anticancer Res. 44, 3713\u20133724 (2024).","journal-title":"Anticancer Res."},{"key":"2769_CR162","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/ijms17060828","volume":"17","author":"S Koido","year":"2016","unstructured":"Koido, S. Dendritic-tumor fusion cell-based cancer vaccines. Int. J. Mol. Sci. 17, 828 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"2769_CR163","first-page":"491","volume":"87","author":"J Datta","year":"2014","unstructured":"Datta, J. et al. Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J. Biol. Med. 87, 491\u2013518 (2014).","journal-title":"Yale J. Biol. Med."},{"key":"2769_CR164","doi-asserted-by":"publisher","first-page":"1376704","DOI":"10.3389\/fimmu.2024.1376704","volume":"15","author":"JB de Oliveira","year":"2024","unstructured":"de Oliveira, J. B. et al. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review. Front. Immunol. 15, 1376704 (2024).","journal-title":"Front. Immunol."},{"key":"2769_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).","journal-title":"Nat. Commun."},{"key":"2769_CR166","doi-asserted-by":"publisher","first-page":"2412876","DOI":"10.1080\/2162402X.2024.2412876","volume":"13","author":"F Borges","year":"2024","unstructured":"Borges, F. et al. Trial watch: anticancer vaccination with dendritic cells. Oncoimmunology 13, 2412876 (2024).","journal-title":"Oncoimmunology"},{"key":"2769_CR167","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CCO.0000000000000815","volume":"34","author":"J Plumas","year":"2022","unstructured":"Plumas, J. Harnessing dendritic cells for innovative therapeutic cancer vaccines. Curr. Opin. Oncol. 34, 161\u2013168 (2022).","journal-title":"Curr. Opin. Oncol."},{"key":"2769_CR168","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38\u201348 (2013).","journal-title":"Immunity"},{"key":"2769_CR169","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.ircmb.2019.07.006","volume":"348","author":"YS Lee","year":"2019","unstructured":"Lee, Y. S. & Radford, K. J. The role of dendritic cells in cancer. Int. Rev. Cell Mol. Biol. 348, 123\u2013178 (2019).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"2769_CR170","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00262-018-2157-5","volume":"67","author":"D Rojas-Sepulveda","year":"2018","unstructured":"Rojas-Sepulveda, D. et al. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunol. Immunother. 67, 1897\u20131910 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2769_CR171","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","volume":"4","author":"M Saxena","year":"2018","unstructured":"Saxena, M. & Bhardwaj, N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119\u2013137 (2018).","journal-title":"Trends Cancer"},{"key":"2769_CR172","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le, D. T., Pardoll, D. M. & Jaffee, E. M. Cellular vaccine approaches. Cancer J. 16, 304\u2013310 (2010).","journal-title":"Cancer J."},{"key":"2769_CR173","doi-asserted-by":"crossref","unstructured":"Fu, C., Zhou, L., Mi, Q. S. & Jiang, A. DC-based vaccines for cancer immunotherapy. Vaccines 8, 706 (2020).","DOI":"10.3390\/vaccines8040706"},{"key":"2769_CR174","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/cells14110812","volume":"14","author":"Y Mehrani","year":"2025","unstructured":"Mehrani, Y. et al. Dendritic cell-based cancer vaccines: the impact of modulating innate lymphoid cells on anti-tumor efficacy. Cells 14, 812 (2025).","journal-title":"Cells"},{"key":"2769_CR175","first-page":"491","volume":"22","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison. Bioact. Mater. 22, 491\u2013517 (2023).","journal-title":"Bioact. Mater."},{"key":"2769_CR176","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"2769_CR177","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20, 33\u201348 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR178","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2217\/nnm-2019-0388","volume":"15","author":"S Zou","year":"2020","unstructured":"Zou, S. et al. Cell membrane-coated nanoparticles: research advances. Nanomedicine 15, 625\u2013641 (2020).","journal-title":"Nanomedicine"},{"key":"2769_CR179","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302131","volume":"10","author":"Q Cheng","year":"2023","unstructured":"Cheng, Q. et al. Genetically engineered-cell-membrane nanovesicles for cancer immunotherapy. Adv. Sci. 10, e2302131 (2023).","journal-title":"Adv. Sci."},{"key":"2769_CR180","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","volume":"17","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Zhao, R. & Nie, G. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat. Protoc. 17, 2240\u20132274 (2022).","journal-title":"Nat. Protoc."},{"key":"2769_CR181","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","volume":"16","author":"MA Morse","year":"2021","unstructured":"Morse, M. A., Gwin, W. R. 3rd & Mitchell, D. A. Vaccine therapies for cancer: then and now. Target Oncol. 16, 121\u2013152 (2021).","journal-title":"Target Oncol."},{"key":"2769_CR182","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/imt-2022-0036","volume":"14","author":"SA Sadeghi Najafabadi","year":"2022","unstructured":"Sadeghi Najafabadi, S. A., Bolhassani, A. & Aghasadeghi, M. R. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy 14, 639\u2013654 (2022).","journal-title":"Immunotherapy"},{"key":"2769_CR183","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.3390\/ijms21176097","volume":"21","author":"H Sun","year":"2020","unstructured":"Sun, H., Burrola, S., Wu, J. & Ding, W. Q. Extracellular vesicles in the development of cancer therapeutics. Int. J. Mol. Sci. 21, 6097 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2769_CR184","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.2147\/IJN.S313912","volume":"16","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Tumor-derived extracellular vesicles: their role in immune cells and immunotherapy. Int. J. Nanomed. 16, 5395\u20135409 (2021).","journal-title":"Int. J. Nanomed."},{"key":"2769_CR185","doi-asserted-by":"publisher","first-page":"1045624","DOI":"10.3389\/fimmu.2022.1045624","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang, S., Sun, J., Dastgheyb, R. M. & Li, Z. Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression. Front. Immunol. 13, 1045624 (2022).","journal-title":"Front. Immunol."},{"key":"2769_CR186","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1111\/cas.15801","volume":"114","author":"ZW Ye","year":"2023","unstructured":"Ye, Z. W., Yu, Z. L., Chen, G. & Jia, J. Extracellular vesicles in tumor angiogenesis and resistance to anti-angiogenic therapy. Cancer Sci. 114, 2739\u20132749 (2023).","journal-title":"Cancer Sci."},{"key":"2769_CR187","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1039\/D2BM01432G","volume":"11","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. \u201cTrojan horse\u201d nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape. Biomater. Sci. 11, 2020\u20132032 (2023).","journal-title":"Biomater. Sci."},{"key":"2769_CR188","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","volume":"298","author":"C Foged","year":"2005","unstructured":"Foged, C., Brodin, B., Frokjaer, S. & Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298, 315\u2013322 (2005).","journal-title":"Int. J. Pharm."},{"key":"2769_CR189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","volume":"40","author":"SD Xiang","year":"2006","unstructured":"Xiang, S. D. et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40, 1\u20139 (2006).","journal-title":"Methods"},{"key":"2769_CR190","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1021\/acs.bioconjchem.7b00669","volume":"29","author":"PY Li","year":"2018","unstructured":"Li, P. Y., Fan, Z. & Cheng, H. Cell membrane bioconjugation and membrane-derived nanomaterials for immunotherapy. Bioconjug. Chem. 29, 624\u2013634 (2018).","journal-title":"Bioconjug. Chem."},{"key":"2769_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01748-4","volume":"20","author":"E Soprano","year":"2022","unstructured":"Soprano, E., Polo, E., Pelaz, B. & Del Pino, P. Biomimetic cell-derived nanocarriers in cancer research. J. Nanobiotechnol. 20, 538 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"2769_CR192","doi-asserted-by":"publisher","first-page":"e2412679","DOI":"10.1002\/smll.202412679","volume":"21","author":"Y Miao","year":"2025","unstructured":"Miao, Y., Ge, J., Zheng, L. & Liu, G. Bioinspired membrane-based cancer vaccines for immunotherapy: progress and perspectives. Small 21, e2412679 (2025).","journal-title":"Small"},{"key":"2769_CR193","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR194","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295\u2013316 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR195","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"2769_CR196","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/2159-8290.CD-20-1211","volume":"11","author":"P Dey","year":"2021","unstructured":"Dey, P., Kimmelman, A. C. & DePinho, R. A. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 11, 1067\u20131081 (2021).","journal-title":"Cancer Discov."},{"key":"2769_CR197","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-030-17864-2_3","volume":"1151","author":"F Garrido","year":"2019","unstructured":"Garrido, F. HLA class-I expression and cancer immunotherapy. Adv. Exp. Med. Biol. 1151, 79\u201390 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2769_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi, J. et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat. Commun. 13, 1742 (2022).","journal-title":"Nat. Commun."},{"key":"2769_CR199","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","volume":"82","author":"E Timperi","year":"2022","unstructured":"Timperi, E. et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 82, 3291\u20133306 (2022).","journal-title":"Cancer Res."},{"key":"2769_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100884","volume":"4","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Current understanding of the intratumoral microbiome in various tumors. Cell Rep. Med. 4, 100884 (2023).","journal-title":"Cell Rep. Med."},{"key":"2769_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","volume":"110","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara, Y. et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat. Rev. 110, 102461 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"2769_CR202","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler, A. & Vignali, D. A. A. T cell exhaustion. Annu. Rev. Immunol. 42, 179\u2013206 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"2769_CR203","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"2769_CR204","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR205","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"2769_CR206","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2012.10.031","volume":"340","author":"S Horswell","year":"2013","unstructured":"Horswell, S., Matthews, N. & Swanton, C. Cancer heterogeneity and \u201cthe struggle for existence\u201d: diagnostic and analytical challenges. Cancer Lett. 340, 220\u2013226 (2013).","journal-title":"Cancer Lett."},{"key":"2769_CR207","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10555-021-09964-4","volume":"40","author":"I Algarra","year":"2021","unstructured":"Algarra, I., Garrido, F. & Garcia-Lora, A. M. MHC heterogeneity and response of metastases to immunotherapy. Cancer Metastasis Rev. 40, 501\u2013517 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2769_CR208","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jhep.2009.11.029","volume":"52","author":"JR Hov","year":"2010","unstructured":"Hov, J. R. et al. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J. Hepatol. 52, 712\u2013717 (2010).","journal-title":"J. Hepatol."},{"key":"2769_CR209","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e1211 (2017).","journal-title":"Cell"},{"key":"2769_CR210","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMcibr1613793","volume":"376","author":"VN Kristensen","year":"2017","unstructured":"Kristensen, V. N. The antigenicity of the tumor cell - context matters. N. Engl. J. Med. 376, 491\u2013493 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2769_CR211","doi-asserted-by":"crossref","unstructured":"Pulendran, B. & Davis, M. M. The science and medicine of human immunology. Science. 369, eaay4014 (2020).","DOI":"10.1126\/science.aay4014"},{"key":"2769_CR212","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser, D. E., Chijioke, O., Schaeuble, K. & Munz, C. CD4(+) T cells in cancer. Nat. Cancer 4, 317\u2013329 (2023).","journal-title":"Nat. Cancer"},{"key":"2769_CR213","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265\u2013277 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR214","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A. et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555 (2002).","journal-title":"Trends Immunol."},{"key":"2769_CR215","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.smim.2007.03.003","volume":"19","author":"C Mazza","year":"2007","unstructured":"Mazza, C. & Malissen, B. What guides MHC-restricted TCR recognition? Semin. Immunol. 19, 225\u2013235 (2007).","journal-title":"Semin. Immunol."},{"key":"2769_CR216","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41577-024-01025-5","volume":"24","author":"I Comerford","year":"2024","unstructured":"Comerford, I. & McColl, S. R. Atypical chemokine receptors in the immune system. Nat. Rev. Immunol. 24, 753\u2013769 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2769_CR217","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.it.2020.06.008","volume":"41","author":"CC Zebley","year":"2020","unstructured":"Zebley, C. C., Gottschalk, S. & Youngblood, B. Rewriting history: epigenetic reprogramming of CD8(+) T cell differentiation to enhance immunotherapy. Trends Immunol. 41, 665\u2013675 (2020).","journal-title":"Trends Immunol."},{"key":"2769_CR218","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41590-023-01664-1","volume":"25","author":"LJ Stern","year":"2024","unstructured":"Stern, L. J., Clement, C., Galluzzi, L. & Santambrogio, L. Non-mutational neoantigens in disease. Nat. Immunol. 25, 29\u201340 (2024).","journal-title":"Nat. Immunol."},{"key":"2769_CR219","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2016.12.039","volume":"392","author":"Z Sun","year":"2017","unstructured":"Sun, Z. et al. MHC class II restricted neoantigen: a promising target in tumor immunotherapy. Cancer Lett. 392, 17\u201325 (2017).","journal-title":"Cancer Lett."},{"key":"2769_CR220","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/14760584.2021.1935248","volume":"20","author":"I Chen","year":"2021","unstructured":"Chen, I., Chen, M. Y., Goedegebuure, S. P. & Gillanders, W. E. Challenges targeting cancer neoantigens in 2021: a systematic literature review. Expert Rev. Vaccines 20, 827\u2013837 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR221","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216.e1208 (2024).","journal-title":"Cancer Cell"},{"key":"2769_CR222","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235\u2013271 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"2769_CR223","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","volume":"17","author":"L Maiorino","year":"2022","unstructured":"Maiorino, L., Dassler-Plenker, J., Sun, L. & Egeblad, M. Innate immunity and cancer pathophysiology. Annu. Rev. Pathol. 17, 425\u2013457 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"2769_CR224","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648\u2013654 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"2769_CR225","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41577-024-01040-6","volume":"24","author":"N Lam","year":"2024","unstructured":"Lam, N., Lee, Y. & Farber, D. L. A guide to adaptive immune memory. Nat. Rev. Immunol. 24, 810\u2013829 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2769_CR226","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255.e236 (2019).","journal-title":"Cancer Cell"},{"key":"2769_CR227","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR228","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q., Sun, Z. & Chen, L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549\u2013564 (2020).","journal-title":"Protein Cell"},{"key":"2769_CR229","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.2023021672","volume":"143","author":"J Duell","year":"2024","unstructured":"Duell, J. et al. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. Blood 143, 685\u2013696 (2024).","journal-title":"Blood"},{"key":"2769_CR230","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR231","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","volume":"24","author":"RM Zemek","year":"2024","unstructured":"Zemek, R. M. et al. Exploiting temporal aspects of cancer immunotherapy. Nat. Rev. Cancer 24, 480\u2013497 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR232","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/gt.2011.17","volume":"18","author":"M Diken","year":"2011","unstructured":"Diken, M. et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 18, 702\u2013708 (2011).","journal-title":"Gene Ther."},{"key":"2769_CR233","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-016-1869-7","volume":"65","author":"A Selmi","year":"2016","unstructured":"Selmi, A. et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol. Immunother. 65, 1075\u20131083 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"2769_CR234","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1073\/pnas.70.2.543","volume":"70","author":"J Brachet","year":"1973","unstructured":"Brachet, J., Huez, G. & Hubert, E. Microinjection of rabbit hemoglobin messenger RNA into amphibian oocytes and embryos. Proc. Natl. Acad. Sci. USA 70, 543\u2013547 (1973).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2769_CR235","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/978-1-62703-260-5_18","volume":"969","author":"N Cools","year":"2013","unstructured":"Cools, N., Van Camp, K., Van Tendeloo, V. & Berneman, Z. mRNA electroporation as a tool for immunomonitoring. Methods Mol. Biol. 969, 293\u2013303 (2013).","journal-title":"Methods Mol. Biol."},{"key":"2769_CR236","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","volume":"118","author":"MP Stewart","year":"2018","unstructured":"Stewart, M. P., Langer, R. & Jensen, K. F. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts. Chem. Rev. 118, 7409\u20137531 (2018).","journal-title":"Chem. Rev."},{"key":"2769_CR237","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig, S. M. et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19, 990\u2013999 (2011).","journal-title":"Mol. Ther."},{"key":"2769_CR238","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.gt.3302964","volume":"14","author":"J Probst","year":"2007","unstructured":"Probst, J. et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14, 1175\u20131180 (2007).","journal-title":"Gene Ther."},{"key":"2769_CR239","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","volume":"70","author":"S Kreiter","year":"2010","unstructured":"Kreiter, S. et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031\u20139040 (2010).","journal-title":"Cancer Res."},{"key":"2769_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1111-6","volume":"15","author":"DK Edwards","year":"2017","unstructured":"Edwards, D. K. et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl. Med. 15, 1 (2017).","journal-title":"J. Transl. Med."},{"key":"2769_CR241","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"JD Beck","year":"2021","unstructured":"Beck, J. D. et al. mRNA therapeutics in cancer immunotherapy. Mol. Cancer 20, 69 (2021).","journal-title":"Mol. Cancer"},{"key":"2769_CR242","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1097\/CM9.0000000000003455","volume":"137","author":"S Huang","year":"2024","unstructured":"Huang, S., Que, H., Wang, M. & Wei, X. mRNA vaccines as cancer therapies. Chin. Med. J. 137, 2979\u20132995 (2024).","journal-title":"Chin. Med. J."},{"key":"2769_CR243","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10238-023-01020-5","volume":"23","author":"Y Mei","year":"2023","unstructured":"Mei, Y. & Wang, X. RNA modification in mRNA cancer vaccines. Clin. Exp. Med. 23, 1917\u20131931 (2023).","journal-title":"Clin. Exp. Med."},{"key":"2769_CR244","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/eji.200425656","volume":"35","author":"B Scheel","year":"2005","unstructured":"Scheel, B. et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. 35, 1557\u20131566 (2005).","journal-title":"Eur. J. Immunol."},{"key":"2769_CR245","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-748","volume":"14","author":"M Sebastian","year":"2014","unstructured":"Sebastian, M. et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14, 748 (2014).","journal-title":"BMC Cancer"},{"key":"2769_CR246","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","volume":"3","author":"H Kubler","year":"2015","unstructured":"Kubler, H. et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study. J. Immunother. Cancer 3, 26 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"2769_CR247","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou, A. et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J. Immunother. Cancer 7, 38 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2769_CR248","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498\u2013507 (2009).","journal-title":"J. Immunother."},{"key":"2769_CR249","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ddr.22076","volume":"84","author":"AM Asrorov","year":"2023","unstructured":"Asrorov, A. M. et al. Cell penetrating peptides: highlighting points in cancer therapy. Drug Dev. Res. 84, 1037\u20131071 (2023).","journal-title":"Drug Dev. Res."},{"key":"2769_CR250","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1016\/j.ymthe.2024.04.035","volume":"32","author":"T Taibi","year":"2024","unstructured":"Taibi, T., Cheon, S., Perna, F. & Vu, L. P. mRNA-based therapeutic strategies for cancer treatment. Mol. Ther. 32, 2819\u20132834 (2024).","journal-title":"Mol. Ther."},{"key":"2769_CR251","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.3390\/nano10122442","volume":"10","author":"M O\u2019Doherty","year":"2020","unstructured":"O\u2019Doherty, M. et al. Improving the intercellular uptake and osteogenic potency of calcium phosphate via nanocomplexation with the RALA peptide. Nanomaterials 10, 2442 (2020).","journal-title":"Nanomaterials"},{"key":"2769_CR252","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2014.06.048","volume":"189","author":"HO McCarthy","year":"2014","unstructured":"McCarthy, H. O. et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J. Control Release 189, 141\u2013149 (2014).","journal-title":"J. Control Release"},{"key":"2769_CR253","doi-asserted-by":"crossref","unstructured":"Udhayakumar, V. K. et al. Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide. Adv. Healthc. Mater. 6, e1601412 (2017).","DOI":"10.1002\/adhm.201601412"},{"key":"2769_CR254","doi-asserted-by":"publisher","first-page":"e0201464","DOI":"10.1371\/journal.pone.0201464","volume":"13","author":"GD Bell","year":"2018","unstructured":"Bell, G. D., Yang, Y., Leung, E. & Krissansen, G. W. mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446. PLoS ONE 13, e0201464 (2018).","journal-title":"PLoS ONE"},{"key":"2769_CR255","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jconrel.2019.08.002","volume":"310","author":"N Tateshita","year":"2019","unstructured":"Tateshita, N. et al. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. J. Control Release 310, 36\u201346 (2019).","journal-title":"J. Control Release"},{"key":"2769_CR256","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jconrel.2020.08.023","volume":"328","author":"R Zhang","year":"2020","unstructured":"Zhang, R. et al. DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine. J. Control Release 328, 210\u2013221 (2020).","journal-title":"J. Control Release"},{"key":"2769_CR257","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acs.bioconjchem.8b00524","volume":"30","author":"B Lou","year":"2019","unstructured":"Lou, B. et al. mRNA polyplexes with post-conjugated GALA peptides efficiently target, transfect, and activate antigen presenting cells. Bioconjug. Chem. 30, 461\u2013475 (2019).","journal-title":"Bioconjug. Chem."},{"key":"2769_CR258","doi-asserted-by":"publisher","first-page":"18801","DOI":"10.1021\/acsnano.4c05065","volume":"18","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Components, formulations, deliveries, and combinations of tumor vaccines. ACS Nano 18, 18801\u201318833 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR259","doi-asserted-by":"publisher","first-page":"115597","DOI":"10.1016\/j.biopha.2023.115597","volume":"167","author":"Priyanka","year":"2023","unstructured":"Priyanka et al. Nanovaccines: a game changing approach in the fight against infectious diseases. Biomed. Pharmacother. 167, 115597 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2769_CR260","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1586\/erv.11.21","volume":"10","author":"VE Schijns","year":"2011","unstructured":"Schijns, V. E. & Lavelle, E. C. Trends in vaccine adjuvants. Expert Rev. Vaccines 10, 539\u2013550 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR261","doi-asserted-by":"publisher","first-page":"S2-44","DOI":"10.1016\/j.vaccine.2005.01.116","volume":"24","author":"J Aucouturier","year":"2006","unstructured":"Aucouturier, J., Ascarateil, S. & Dupuis, L. The use of oil adjuvants in therapeutic vaccines. Vaccine 24, S2-44\u2013S2-445 (2006).","journal-title":"Vaccine"},{"key":"2769_CR262","doi-asserted-by":"publisher","first-page":"e004709","DOI":"10.1136\/jitc-2022-004709","volume":"10","author":"MM Melssen","year":"2022","unstructured":"Melssen, M. M., Fisher, C. T., Slingluff, C. L. & Melief, C. J. M. Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer. J. Immunother. Cancer 10, e004709 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2769_CR263","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijpharm.2013.05.028","volume":"453","author":"M Kalariya","year":"2013","unstructured":"Kalariya, M. & Amiji, M. M. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems. Int. J. Pharm. 453, 400\u2013407 (2013).","journal-title":"Int. J. Pharm."},{"key":"2769_CR264","doi-asserted-by":"publisher","first-page":"940047","DOI":"10.3389\/fimmu.2022.940047","volume":"13","author":"W Lee","year":"2022","unstructured":"Lee, W. & Suresh, M. Vaccine adjuvants to engage the cross-presentation pathway. Front.Immunol. 13, 940047 (2022).","journal-title":"Front.Immunol."},{"key":"2769_CR265","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.apcsb.2015.03.004","volume":"99","author":"Y Lee","year":"2015","unstructured":"Lee, Y., Lee, Y. S., Cho, S. Y. & Kwon, H. J. Perspective of peptide vaccine composed of epitope peptide, CpG-DNA, and liposome complex without carriers. Adv. Protein Chem. Struct. Biol. 99, 75\u201397 (2015).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"2769_CR266","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.0818-9641.2004.01279.x","volume":"82","author":"C Mesa","year":"2004","unstructured":"Mesa, C. & Fernandez, L. E. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol. 82, 644\u2013650 (2004).","journal-title":"Immunol. Cell Biol."},{"key":"2769_CR267","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/v16121933","volume":"16","author":"MM Ahmed","year":"2024","unstructured":"Ahmed, M. M. et al. Vesicular stomatitis virus: insights into pathogenesis, immune evasion, and technological innovations in oncolytic and vaccine development. Viruses 16, 1933 (2024).","journal-title":"Viruses"},{"key":"2769_CR268","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/v17010016","volume":"17","author":"AA Abdelmageed","year":"2024","unstructured":"Abdelmageed, A. A., Dewhurst, S. & Ferran, M. C. Employing the oncolytic vesicular stomatitis virus in cancer virotherapy: resistance and clinical considerations. Viruses 17, 16 (2024).","journal-title":"Viruses"},{"key":"2769_CR269","doi-asserted-by":"publisher","first-page":"e20221166","DOI":"10.1084\/jem.20221166","volume":"220","author":"N Yang","year":"2023","unstructured":"Yang, N. et al. OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. J. Exp. Med. 220, e20221166 (2023).","journal-title":"J. Exp. Med."},{"key":"2769_CR270","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/21645515.2017.1334746","volume":"13","author":"K Bendjama","year":"2017","unstructured":"Bendjama, K. & Quemeneur, E. Modified vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Hum. Vaccin Immunother. 13, 1997\u20132003 (2017).","journal-title":"Hum. Vaccin Immunother."},{"key":"2769_CR271","doi-asserted-by":"crossref","unstructured":"Ferrucci, P. F., Pala, L., Conforti, F. & Cocorocchio, E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers 13, 1383 (2021).","DOI":"10.3390\/cancers13061383"},{"key":"2769_CR272","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-018-0070-z","volume":"18","author":"S Zhou","year":"2018","unstructured":"Zhou, S., Gravekamp, C., Bermudes, D. & Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727\u2013743 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR273","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1126\/science.add9667","volume":"378","author":"CR Gurbatri","year":"2022","unstructured":"Gurbatri, C. R., Arpaia, N. & Danino, T. Engineering bacteria as interactive cancer therapies. Science 378, 858\u2013864 (2022).","journal-title":"Science"},{"key":"2769_CR274","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"SY Kwon","year":"2024","unstructured":"Kwon, S. Y. et al. Exploiting bacteria for cancer immunotherapy. Nat. Rev. Clin. Oncol. 21, 569\u2013589 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2769_CR275","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti, A. et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635, 453\u2013461 (2024).","journal-title":"Nature"},{"key":"2769_CR276","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","volume":"6","author":"Y Yue","year":"2022","unstructured":"Yue, Y. et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat. Biomed. Eng. 6, 898\u2013909 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2769_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22308-8","volume":"12","author":"K Cheng","year":"2021","unstructured":"Cheng, K. et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nat. Commun. 12, 2041 (2021).","journal-title":"Nat. Commun."},{"key":"2769_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92875-9","volume":"11","author":"L Su","year":"2021","unstructured":"Su, L. et al. Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model. Sci. Rep. 11, 13404 (2021).","journal-title":"Sci. Rep."},{"key":"2769_CR279","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003572","volume":"8","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Bacteria-based cancer immunotherapy. Adv. Sci. 8, 2003572 (2021).","journal-title":"Adv. Sci."},{"key":"2769_CR280","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.3390\/pharmaceutics13111892","volume":"13","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. Bacterial ghosts-based vaccine and drug delivery systems. Pharmaceutics 13, 1892 (2021).","journal-title":"Pharmaceutics"},{"key":"2769_CR281","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14760584.2018.1455505","volume":"17","author":"AF Sander","year":"2018","unstructured":"Sander, A. F. & Lollini, P. L. Virus-like antigen display for cancer vaccine development, what is the potential? Expert Rev. Vaccines 17, 285\u2013288 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR282","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja, J. et al. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer 6, 140 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2769_CR283","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","volume":"7","author":"ZS Guo","year":"2019","unstructured":"Guo, Z. S. et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J. Immunother. Cancer 7, 6 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2769_CR284","doi-asserted-by":"publisher","first-page":"2379086","DOI":"10.1080\/21645515.2024.2379086","volume":"20","author":"GC Giudice","year":"2024","unstructured":"Giudice, G. C. & Sonpavde, G. P. Vaccine approaches to treat urothelial cancer. Hum. Vaccin Immunother. 20, 2379086 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"2769_CR285","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41417-022-00499-6","volume":"30","author":"GP Dailey","year":"2023","unstructured":"Dailey, G. P., Crosby, E. J. & Hartman, Z. C. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 30, 794\u2013802 (2023).","journal-title":"Cancer Gene Ther."},{"key":"2769_CR286","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101349","volume":"11","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. White blood cell membrane-coated nanoparticles: recent development and medical applications. Adv. Health. Mater. 11, e2101349 (2022).","journal-title":"Adv. Health. Mater."},{"key":"2769_CR287","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.drup.2024.101098","volume":"75","author":"Z Xu","year":"2024","unstructured":"Xu, Z. et al. Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance. Drug Resist. Updat. 75, 101098 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2769_CR288","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res 27, 74\u201395 (2017).","journal-title":"Cell Res"},{"key":"2769_CR289","doi-asserted-by":"publisher","first-page":"2096363","DOI":"10.1080\/2162402X.2022.2096363","volume":"11","author":"RS Laureano","year":"2022","unstructured":"Laureano, R. S. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology 11, 2096363 (2022).","journal-title":"Oncoimmunology"},{"key":"2769_CR290","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","volume":"9","author":"Y Guo","year":"2015","unstructured":"Guo, Y. et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 9, 6918\u20136933 (2015).","journal-title":"ACS Nano"},{"key":"2769_CR291","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-bioeng-121219-024239","volume":"23","author":"JS Brenner","year":"2021","unstructured":"Brenner, J. S., Mitragotri, S. & Muzykantov, V. R. Red blood cell hitchhiking: a novel approach for vascular delivery of nanocarriers. Annu. Rev. Biomed. Eng. 23, 225\u2013248 (2021).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"2769_CR292","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202501616","volume":"37","author":"N Krishnan","year":"2025","unstructured":"Krishnan, N. et al. Universal prophylactic antitumor vaccination using stem cell membrane-coated nanoparticles. Adv. Mater. 37, e2501616 (2025).","journal-title":"Adv. Mater."},{"key":"2769_CR293","first-page":"1","volume":"21","author":"BQ Chen","year":"2023","unstructured":"Chen, B. Q. et al. Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy. Bioact. Mater. 21, 1\u201319 (2023).","journal-title":"Bioact. Mater."},{"key":"2769_CR294","doi-asserted-by":"publisher","first-page":"102116","DOI":"10.1016\/j.mtbio.2025.102116","volume":"34","author":"D Wusiman","year":"2025","unstructured":"Wusiman, D. et al. Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation. Mater. Today Bio 34, 102116 (2025).","journal-title":"Mater. Today Bio"},{"key":"2769_CR295","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173\u2013200 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2769_CR296","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607\u2013625 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2769_CR297","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","volume":"196","author":"Q Song","year":"2018","unstructured":"Song, Q., Zhang, C. D. & Wu, X. H. Therapeutic cancer vaccines: from initial findings to prospects. Immunol. Lett. 196, 11\u201321 (2018).","journal-title":"Immunol. Lett."},{"key":"2769_CR298","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","volume":"71","author":"V Corbiere","year":"2011","unstructured":"Corbiere, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253\u20131262 (2011).","journal-title":"Cancer Res."},{"key":"2769_CR299","doi-asserted-by":"publisher","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl. Cancer Inst. 109, djw261 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"2769_CR300","first-page":"1825","volume":"325","author":"J Abbasi","year":"2021","unstructured":"Abbasi, J. Personalized cancer vaccine approach safe in early trial. JAMA 325, 1825 (2021).","journal-title":"JAMA"},{"key":"2769_CR301","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/14760584.2021.1909479","volume":"20","author":"X Xu","year":"2021","unstructured":"Xu, X., Zhou, Z., Li, H. & Fan, Y. Towards customized cancer vaccines: a promising filed in personalized cancer medicine. Expert Rev. Vaccines 20, 545\u2013557 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR302","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/nl500618u","volume":"14","author":"RH Fang","year":"2014","unstructured":"Fang, R. H. et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14, 2181\u20132188 (2014).","journal-title":"Nano Lett."},{"key":"2769_CR303","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1021\/acsnano.8b07371","volume":"13","author":"X Ye","year":"2019","unstructured":"Ye, X. et al. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS Nano 13, 2956\u20132968 (2019).","journal-title":"ACS Nano"},{"key":"2769_CR304","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41551-021-00795-w","volume":"6","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns. Nat. Biomed. Eng. 6, 19\u201331 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2769_CR305","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1172\/JCI95148","volume":"128","author":"N Herranz","year":"2018","unstructured":"Herranz, N. & Gil, J. Mechanisms and functions of cellular senescence. J. Clin. Invest. 128, 1238\u20131246 (2018).","journal-title":"J. Clin. Invest."},{"key":"2769_CR306","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s12276-023-00951-z","volume":"55","author":"J Hong","year":"2023","unstructured":"Hong, J. et al. Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine. Exp. Mol. Med. 55, 541\u2013554 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2769_CR307","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","volume":"15","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043\u20131052 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2769_CR308","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202109254","volume":"34","author":"J Zhao","year":"2022","unstructured":"Zhao, J. et al. A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy. Adv. Mater. 34, e2109254 (2022).","journal-title":"Adv. Mater."},{"key":"2769_CR309","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303979","volume":"35","author":"S Go","year":"2023","unstructured":"Go, S. et al. A personalized cancer nanovaccine that enhances T-cell responses and efficacy through dual interactions with dendritic cells and T cells. Adv. Mater. 35, e2303979 (2023).","journal-title":"Adv. Mater."},{"key":"2769_CR310","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jconrel.2020.07.008","volume":"326","author":"J Gan","year":"2020","unstructured":"Gan, J. et al. Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. J. Control Release 326, 297\u2013309 (2020).","journal-title":"J. Control Release"},{"key":"2769_CR311","doi-asserted-by":"publisher","first-page":"9410","DOI":"10.1021\/acs.nanolett.1c02582","volume":"21","author":"B Liu","year":"2021","unstructured":"Liu, B. et al. Equipping cancer cell membrane vesicles with functional DNA as a targeted vaccine for cancer immunotherapy. Nano Lett. 21, 9410\u20139418 (2021).","journal-title":"Nano Lett."},{"key":"2769_CR312","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202104849","volume":"33","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells. Adv. Mater. 33, e2104849 (2021).","journal-title":"Adv. Mater."},{"key":"2769_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114107","volume":"182","author":"Z Meng","year":"2022","unstructured":"Meng, Z. et al. Nanovaccines with cell-derived components for cancer immunotherapy. Adv. Drug Deliv. Rev. 182, 114107 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2769_CR314","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14760584.2021.1984890","volume":"20","author":"A Das","year":"2021","unstructured":"Das, A. & Ali, N. Nanovaccine: an emerging strategy. Expert Rev. Vaccines 20, 1273\u20131290 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR315","first-page":"30","volume":"17","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Engineered cancer nanovaccines: a new frontier in cancer therapy. Nanomicro Lett. 17, 30 (2024).","journal-title":"Nanomicro Lett."},{"key":"2769_CR316","doi-asserted-by":"publisher","first-page":"122856","DOI":"10.1016\/j.biomaterials.2024.122856","volume":"314","author":"K Poudel","year":"2025","unstructured":"Poudel, K., Vithiananthan, T., Kim, J. O. & Tsao, H. Recent progress in cancer vaccines and nanovaccines. Biomaterials 314, 122856 (2025).","journal-title":"Biomaterials"},{"key":"2769_CR317","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230164","volume":"4","author":"Y He","year":"2024","unstructured":"He, Y. et al. Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy. Exploration 4, 20230164 (2024).","journal-title":"Exploration"},{"key":"2769_CR318","doi-asserted-by":"publisher","first-page":"627932","DOI":"10.3389\/fimmu.2021.627932","volume":"12","author":"SJ Paston","year":"2021","unstructured":"Paston, S. J., Brentville, V. A., Symonds, P. & Durrant, L. G. Cancer vaccines, adjuvants, and delivery systems. Front. Immunol. 12, 627932 (2021).","journal-title":"Front. Immunol."},{"key":"2769_CR319","doi-asserted-by":"publisher","first-page":"109887","DOI":"10.1016\/j.intimp.2023.109887","volume":"117","author":"N Hashemi Goradel","year":"2023","unstructured":"Hashemi Goradel, N. et al. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen. Int. Immunopharmacol. 117, 109887 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2769_CR320","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1021\/acs.nanolett.2c04970","volume":"23","author":"ZL Gao","year":"2023","unstructured":"Gao, Z. L. et al. Orchestrated cytosolic delivery of antigen and adjuvant by manganese ion-coordinated nanovaccine for enhanced cancer immunotherapy. Nano Lett. 23, 1904\u20131913 (2023).","journal-title":"Nano Lett."},{"key":"2769_CR321","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122062","volume":"296","author":"S Manna","year":"2023","unstructured":"Manna, S. et al. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials 296, 122062 (2023).","journal-title":"Biomaterials"},{"key":"2769_CR322","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","volume":"18","author":"JJ Baljon","year":"2024","unstructured":"Baljon, J. J. et al. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano 18, 6845\u20136862 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR323","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk2444","volume":"10","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci. Adv. 10, eadk2444 (2024).","journal-title":"Sci. Adv."},{"key":"2769_CR324","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6071","volume":"6","author":"Q Ni","year":"2020","unstructured":"Ni, Q. et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci. Adv. 6, eaaw6071 (2020).","journal-title":"Sci. Adv."},{"key":"2769_CR325","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye, K. R. et al. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol. Cancer 22, 160 (2023).","journal-title":"Mol. Cancer"},{"key":"2769_CR326","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/1061186X.2017.1367006","volume":"26","author":"RR Wakaskar","year":"2018","unstructured":"Wakaskar, R. R. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J. Drug Target. 26, 311\u2013318 (2018).","journal-title":"J. Drug Target."},{"key":"2769_CR327","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jcis.2020.08.010","volume":"582","author":"Y Gao","year":"2021","unstructured":"Gao, Y. et al. Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers. J. Colloid Interface Sci. 582, 364\u2013375 (2021).","journal-title":"J. Colloid Interface Sci."},{"key":"2769_CR328","first-page":"34","volume":"11","author":"KN Yang","year":"2014","unstructured":"Yang, K. N. et al. pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol. Med. 11, 34\u201343 (2014).","journal-title":"Cancer Biol. Med."},{"key":"2769_CR329","doi-asserted-by":"publisher","first-page":"15758","DOI":"10.1021\/acs.nanolett.4c04557","volume":"24","author":"L Luo","year":"2024","unstructured":"Luo, L. et al. A bioinspired nanovaccine for personalized cancer immunotherapy. Nano Lett. 24, 15758\u201315766 (2024).","journal-title":"Nano Lett."},{"key":"2769_CR330","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1021\/acsnano.4c11014","volume":"19","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Personalized nanovaccine based on STING-activating nanocarrier for robust cancer immunotherapy. ACS Nano 19, 3226\u20133239 (2025).","journal-title":"ACS Nano"},{"key":"2769_CR331","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","volume":"353","author":"J Li","year":"2023","unstructured":"Li, J. et al. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J. Control Release 353, 423\u2013433 (2023).","journal-title":"J. Control Release"},{"key":"2769_CR332","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202409590","volume":"36","author":"L Qu","year":"2024","unstructured":"Qu, L. et al. A biomimetic autophagosomes-based nanovaccine boosts anticancer immunity. Adv. Mater. 36, e2409590 (2024).","journal-title":"Adv. Mater."},{"key":"2769_CR333","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41565-024-01826-8","volume":"20","author":"WQ Huang","year":"2025","unstructured":"Huang, W. Q. et al. Autophagosomes coated in situ with nanodots act as personalized cancer vaccines. Nat. Nanotechnol. 20, 451\u2013462 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"2769_CR334","doi-asserted-by":"publisher","first-page":"11910","DOI":"10.1021\/acsnano.4c01691","volume":"18","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Expanding the potential of neoantigen vaccines: harnessing bacille calmette-guerin cell-wall-based nanoscale adjuvants for enhanced cancer immunotherapy. ACS Nano 18, 11910\u201311920 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR335","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202209910","volume":"35","author":"F Chen","year":"2023","unstructured":"Chen, F. et al. Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer. Adv. Mater. 35, e2209910 (2023).","journal-title":"Adv. Mater."},{"key":"2769_CR336","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121794","volume":"289","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. Biomaterials 289, 121794 (2022).","journal-title":"Biomaterials"},{"key":"2769_CR337","doi-asserted-by":"publisher","first-page":"7136","DOI":"10.1021\/acsnano.3c11637","volume":"18","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Self-adjuvanting polyguanidine nanovaccines for cancer immunotherapy. ACS Nano 18, 7136\u20137147 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR338","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2022.140930","volume":"456","author":"J Li","year":"2023","unstructured":"Li, J. et al. Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. Chem. Eng. J. 456, 140930 (2023).","journal-title":"Chem. Eng. J."},{"key":"2769_CR339","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin, D. et al. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat. Biomed. Eng. 9, 185\u2013200 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"2769_CR340","doi-asserted-by":"publisher","first-page":"122703","DOI":"10.1016\/j.ijpharm.2023.122703","volume":"635","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Dendritic cell-targeting polymer nanoparticle-based immunotherapy for cancer: a review. Int. J. Pharm. 635, 122703 (2023).","journal-title":"Int. J. Pharm."},{"key":"2769_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60448-3","volume":"16","author":"K Feng","year":"2025","unstructured":"Feng, K. et al. Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment. Nat. Commun. 16, 5074 (2025).","journal-title":"Nat. Commun."},{"key":"2769_CR342","doi-asserted-by":"crossref","unstructured":"Xiong, J. et al. CpG-based nanovaccines enhance ovarian cancer immune response by Gbp2-mediated remodeling of tumor-associated macrophages. Adv. Sci. 12, e2412881 (2025).","DOI":"10.1002\/advs.202412881"},{"key":"2769_CR343","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat. Commun. 14, 1610 (2023).","journal-title":"Nat. Commun."},{"key":"2769_CR344","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101788","volume":"11","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. CD47- and integrin alpha4\/beta1-comodified-macrophage-membrane-coated nanoparticles enable delivery of colchicine to atherosclerotic plaque. Adv. Health. Mater. 11, e2101788 (2022).","journal-title":"Adv. Health. Mater."},{"key":"2769_CR345","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/pharmaceutics15061685","volume":"15","author":"AS Dossou","year":"2023","unstructured":"Dossou, A. S. et al. Mannose-coated reconstituted lipoprotein nanoparticles for the targeting of tumor-associated macrophages: optimization, characterization, and in vitro evaluation of effectiveness. Pharmaceutics 15, 1685 (2023).","journal-title":"Pharmaceutics"},{"key":"2769_CR346","doi-asserted-by":"crossref","unstructured":"Wang, Z. B. & Xu, J. Better adjuvants for better vaccines: progress in adjuvant delivery systems, modifications, and adjuvant-antigen codelivery. Vaccines 8, 128 (2020).","DOI":"10.3390\/vaccines8010128"},{"key":"2769_CR347","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1021\/acsami.8b20364","volume":"11","author":"X Dong","year":"2019","unstructured":"Dong, X. et al. A visible codelivery nanovaccine of antigen and adjuvant with self-carrier for cancer immunotherapy. ACS Appl. Mater. Interfaces 11, 4876\u20134888 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2769_CR348","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/2326-6066.CIR-23-0926","volume":"12","author":"H Pan","year":"2024","unstructured":"Pan, H. et al. Orchestrated codelivery of peptide antigen and adjuvant to antigen-presenting cells by using an engineered chimeric peptide enhances antitumor T-cell immunity. Cancer Immunol. Res. 12, 905\u2013920 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2769_CR349","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.fmre.2021.11.032","volume":"2","author":"J Liang","year":"2022","unstructured":"Liang, J. et al. Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells. Fundam. Res. 2, 23\u201336 (2022).","journal-title":"Fundam. Res."},{"key":"2769_CR350","doi-asserted-by":"publisher","first-page":"eabc2816","DOI":"10.1126\/scitranslmed.abc2816","volume":"13","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2769_CR351","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308235","volume":"11","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Hybrid ginseng-derived extracellular vesicles-like particles with autologous tumor cell membrane for personalized vaccination to inhibit tumor recurrence and metastasis. Adv. Sci. 11, e2308235 (2024).","journal-title":"Adv. Sci."},{"key":"2769_CR352","doi-asserted-by":"publisher","first-page":"102648","DOI":"10.1016\/j.nano.2022.102648","volume":"48","author":"L Shi","year":"2023","unstructured":"Shi, L. & Gu, H. Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer vaccine therapy. Nanomedicine 48, 102648 (2023).","journal-title":"Nanomedicine"},{"key":"2769_CR353","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59977-8","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy. Nat. Commun. 16, 4783 (2025).","journal-title":"Nat. Commun."},{"key":"2769_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101877","volume":"6","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Neoadjuvant chemotherapy by liposomal doxorubicin boosts immune protection of tumor membrane antigens-based nanovaccine. Cell Rep. Med. 6, 101877 (2025).","journal-title":"Cell Rep. Med."},{"key":"2769_CR355","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41565-025-01931-2","volume":"20","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. Engineering pyroptotic vesicles as personalized cancer vaccines. Nat. Nanotechnol. 20, 1108\u20131118 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"2769_CR356","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/14760584.2023.2274479","volume":"22","author":"S Zhou","year":"2023","unstructured":"Zhou, S., Luo, Y. & Lovell, J. F. Vaccine approaches for antigen capture by liposomes. Expert Rev. Vaccines 22, 1022\u20131040 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR357","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306336","volume":"11","author":"P Bao","year":"2024","unstructured":"Bao, P. et al. Chimeric exosomes functionalized with STING activation for personalized glioblastoma immunotherapy. Adv. Sci. 11, e2306336 (2024).","journal-title":"Adv. Sci."},{"key":"2769_CR358","doi-asserted-by":"crossref","unstructured":"Fontana, F., Liu, D., Hirvonen, J. & Santos, H. A. Delivery of therapeutics with nanoparticles: what\u2019s new in cancer immunotherapy? Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 9, e1421 (2017).","DOI":"10.1002\/wnan.1421"},{"key":"2769_CR359","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1039\/D2CS00647B","volume":"52","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Yang, B., Ni, Q. & Chen, X. Materials engineering strategies for cancer vaccine adjuvant development. Chem. Soc. Rev. 52, 2886\u20132910 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"2769_CR360","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","volume":"17","author":"WS Bowen","year":"2018","unstructured":"Bowen, W. S. et al. Current challenges for cancer vaccine adjuvant development. Expert Rev. Vaccines 17, 207\u2013215 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"2769_CR361","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2018.12.028","volume":"85","author":"P Huang","year":"2019","unstructured":"Huang, P. et al. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater. 85, 1\u201326 (2019).","journal-title":"Acta Biomater."},{"key":"2769_CR362","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40580-021-00282-7","volume":"8","author":"JA Kemp","year":"2021","unstructured":"Kemp, J. A. & Kwon, Y. J. Cancer nanotechnology: current status and perspectives. Nano Converg. 8, 34 (2021).","journal-title":"Nano Converg."},{"key":"2769_CR363","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek, M. et al. Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells 12, 2159 (2023).","journal-title":"Cells"},{"key":"2769_CR364","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu, S. et al. Combination strategies to maximize the benefits of cancer immunotherapy. J. Hematol. Oncol. 14, 156 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2769_CR365","doi-asserted-by":"publisher","first-page":"961805","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Clinical cancer immunotherapy: current progress and prospects. Front. Immunol. 13, 961805 (2022).","journal-title":"Front. Immunol."},{"key":"2769_CR366","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"WD Yu","year":"2019","unstructured":"Yu, W. D. et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 452, 66\u201370 (2019).","journal-title":"Cancer Lett."},{"key":"2769_CR367","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.3390\/cancers14163842","volume":"14","author":"X Fang","year":"2022","unstructured":"Fang, X. et al. Nanovaccines for cancer prevention and immunotherapy: an update review. Cancers 14, 3842 (2022).","journal-title":"Cancers"},{"key":"2769_CR368","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200673","volume":"18","author":"QT Wang","year":"2023","unstructured":"Wang, Q. T., Liu, Y. X., Wang, J. & Wang, H. Advances in cancer nanovaccines: harnessing nanotechnology for broadening cancer immune response. ChemMedChem 18, e202200673 (2023).","journal-title":"ChemMedChem"},{"key":"2769_CR369","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","volume":"17","author":"T Feng","year":"2024","unstructured":"Feng, T. et al. Personalized nanovaccines for treating solid cancer metastases. J. Hematol. Oncol. 17, 115 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2769_CR370","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125223","volume":"242","author":"M Jiang","year":"2023","unstructured":"Jiang, M. et al. Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle. Int. J. Biol. Macromol. 242, 125223 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"2769_CR371","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 19, 59 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"2769_CR372","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.drudis.2021.10.007","volume":"27","author":"M Alavi","year":"2022","unstructured":"Alavi, M. & Nokhodchi, A. Micro- and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: Recent advances and challenges. Drug Discov. Today 27, 576\u2013584 (2022).","journal-title":"Drug Discov. Today"},{"key":"2769_CR373","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv. Mater. 33, e2007603 (2021).","journal-title":"Adv. Mater."},{"key":"2769_CR374","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122104","volume":"297","author":"L Chang","year":"2023","unstructured":"Chang, L. et al. Regulating T-cell metabolic reprogramming and blocking PD-1 co-promote personalized postoperative autologous nanovaccines. Biomaterials 297, 122104 (2023).","journal-title":"Biomaterials"},{"key":"2769_CR375","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jare.2021.08.011","volume":"35","author":"M Jiang","year":"2022","unstructured":"Jiang, M. et al. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy. J. Adv. Res. 35, 49\u201360 (2022).","journal-title":"J. Adv. Res."},{"key":"2769_CR376","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300299","volume":"10","author":"AI Matos","year":"2023","unstructured":"Matos, A. I. et al. Polyoxazoline-based nanovaccine synergizes with tumor-associated macrophage targeting and anti-PD-1 immunotherapy against solid tumors. Adv. Sci. 10, e2300299 (2023).","journal-title":"Adv. Sci."},{"key":"2769_CR377","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1016\/j.apsb.2024.03.023","volume":"14","author":"Q Tang","year":"2024","unstructured":"Tang, Q. et al. Nanoparticle drug delivery system for the treatment of brain tumors: breaching the blood-brain barrier. Acta Pharm. Sin. B 14, 2786\u20132789 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2769_CR378","doi-asserted-by":"crossref","unstructured":"Zhang, N. et al. Dendritic mesoporous silica nanoparticle supported PtSn catalysts for propane dehydrogenation. Int. J. Mol. Sci. 23, 12724 (2022).","DOI":"10.3390\/ijms232112724"},{"key":"2769_CR379","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202112752","volume":"61","author":"C Xu","year":"2022","unstructured":"Xu, C., Lei, C., Wang, Y. & Yu, C. Dendritic mesoporous nanoparticles: structure, synthesis and properties. Angew. Chem. Int. Ed. Engl. 61, e202112752 (2022).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2769_CR380","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2019.02.036","volume":"300","author":"M Luo","year":"2019","unstructured":"Luo, M. et al. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. J. Control Release 300, 154\u2013160 (2019).","journal-title":"J. Control Release"},{"key":"2769_CR381","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.1021\/acsnano.3c11960","volume":"18","author":"M Chang","year":"2024","unstructured":"Chang, M. et al. A cancer nanovaccine based on an FeAl-layered double hydroxide framework for reactive oxygen species-augmented metalloimmunotherapy. ACS Nano 18, 8143\u20138156 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR382","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","volume":"14","author":"J Conniot","year":"2019","unstructured":"Conniot, J. et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 14, 891\u2013901 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"2769_CR383","doi-asserted-by":"publisher","first-page":"36824","DOI":"10.1021\/acsami.1c08201","volume":"13","author":"Q Song","year":"2021","unstructured":"Song, Q. et al. Reinforcing the combinational immuno-oncotherapy of switching \u201ccold\u201d tumor to \u201chot\u201d by responsive penetrating nanogels. ACS Appl Mater. Interfaces 13, 36824\u201336838 (2021).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2769_CR384","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1021\/acsnano.3c08376","volume":"18","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Injectable nano-in-gel vaccine for spatial and temporal control of vaccine kinetics and breast cancer postsurgical therapy. ACS Nano 18, 3087\u20133100 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR385","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202205950","volume":"34","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines. Adv. Mater. 34, e2205950 (2022).","journal-title":"Adv. Mater."},{"key":"2769_CR386","first-page":"3036","volume":"6","author":"F Yang","year":"2021","unstructured":"Yang, F. et al. Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner. Bioact. Mater. 6, 3036\u20133048 (2021).","journal-title":"Bioact. Mater."},{"key":"2769_CR387","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.actbio.2022.12.070","volume":"158","author":"H Song","year":"2023","unstructured":"Song, H. et al. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. Acta Biomater. 158, 535\u2013546 (2023).","journal-title":"Acta Biomater."},{"key":"2769_CR388","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210452","volume":"36","author":"Y Bo","year":"2024","unstructured":"Bo, Y. & Wang, H. Biomaterial-based in situ cancer vaccines. Adv. Mater. 36, e2210452 (2024).","journal-title":"Adv. Mater."},{"key":"2769_CR389","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcis.2023.01.107","volume":"638","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Copper indium sulfide quantum dots in photocatalysis. J. Colloid Interface Sci. 638, 193\u2013219 (2023).","journal-title":"J. Colloid Interface Sci."},{"key":"2769_CR390","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121808","volume":"289","author":"D Huang","year":"2022","unstructured":"Huang, D. et al. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials 289, 121808 (2022).","journal-title":"Biomaterials"},{"key":"2769_CR391","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.2217\/nnm-2023-0202","volume":"18","author":"WJ Chan","year":"2023","unstructured":"Chan, W. J., Urandur, S., Li, H. & Goudar, V. S. Recent advances in copper sulfide nanoparticles for phototherapy of bacterial infections and cancer. Nanomedicine 18, 2185\u20132204 (2023).","journal-title":"Nanomedicine"},{"key":"2769_CR392","doi-asserted-by":"publisher","first-page":"32088","DOI":"10.1021\/acsnano.4c10688","volume":"18","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Potent amphiphilic poly(amino acid) nanoadjuvant delivers biomineralized ovalbumin for photothermal-augmented immunotherapy. ACS Nano 18, 32088\u201332102 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR393","doi-asserted-by":"publisher","first-page":"12250","DOI":"10.1039\/C9NR02463H","volume":"11","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. Porphyrin-based metal-organic frameworks: protonation induced Q band absorption. Nanoscale 11, 12250\u201312258 (2019).","journal-title":"Nanoscale"},{"key":"2769_CR394","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40851-4","volume":"14","author":"H Qin","year":"2023","unstructured":"Qin, H. et al. Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation. Nat. Commun. 14, 5178 (2023).","journal-title":"Nat. Commun."},{"key":"2769_CR395","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1039\/C9CS00648F","volume":"49","author":"S Son","year":"2020","unstructured":"Son, S. et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem. Soc. Rev. 49, 3244\u20133261 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"2769_CR396","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1080\/1061186X.2018.1527338","volume":"27","author":"S Cesmeli","year":"2019","unstructured":"Cesmeli, S. & Biray Avci, C. Application of titanium dioxide (TiO(2)) nanoparticles in cancer therapies. J. Drug Target. 27, 762\u2013766 (2019).","journal-title":"J. Drug Target."},{"key":"2769_CR397","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.phrs.2024.107331","volume":"207","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Bugs as drugs: extended clinical applications and potential translational trends of Akkermansia muciniphila in oncology and comprehensive clinical investigation panorama of therapeutic microbiome modulators in gastric cancer treatment. Pharm. Res. 207, 107331 (2024).","journal-title":"Pharm. Res."},{"key":"2769_CR398","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202203100","volume":"18","author":"X Li","year":"2022","unstructured":"Li, X. et al. In situ antigen-capturing nanochaperone toward personalized nanovaccine for cancer immunotherapy. Small 18, e2203100 (2022).","journal-title":"Small"},{"key":"2769_CR399","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","volume":"44","author":"Y Fang","year":"2023","unstructured":"Fang, Y. et al. Targeted protein degrader development for cancer: advances, challenges, and opportunities. Trends Pharmacol. Sci. 44, 303\u2013317 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"2769_CR400","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202301041","volume":"19","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. In situ tumor vaccine for lymph nodes delivery and cancer therapy based on small size nanoadjuvant. Small 19, e2301041 (2023).","journal-title":"Small"},{"key":"2769_CR401","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1021\/acsnano.7b00978","volume":"11","author":"G Zhu","year":"2017","unstructured":"Zhu, G. et al. Efficient nanovaccine delivery in cancer immunotherapy. ACS Nano 11, 2387\u20132392 (2017).","journal-title":"ACS Nano"},{"key":"2769_CR402","first-page":"53","volume":"9","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil. Med. Res. 9, 53 (2022).","journal-title":"Mil. Med. Res."},{"key":"2769_CR403","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.cell.2024.03.038","volume":"187","author":"R Medzhitov","year":"2024","unstructured":"Medzhitov, R. & Iwasaki, A. Exploring new perspectives in immunology. Cell 187, 2079\u20132094 (2024).","journal-title":"Cell"},{"key":"2769_CR404","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.cell.2024.03.036","volume":"187","author":"S Carpenter","year":"2024","unstructured":"Carpenter, S. & O\u2019Neill, L. A. J. From periphery to center stage: 50 years of advancements in innate immunity. Cell 187, 2030\u20132051 (2024).","journal-title":"Cell"},{"key":"2769_CR405","doi-asserted-by":"publisher","first-page":"53474","DOI":"10.1021\/acsami.4c09825","volume":"16","author":"D Lu","year":"2024","unstructured":"Lu, D. et al. STING agonist delivered by neutrophil membrane-coated gold nanoparticles exerts synergistic tumor inhibition with radiotherapy. ACS Appl. Mater. Interfaces 16, 53474\u201353488 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2769_CR406","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02993-5","volume":"22","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. IL-7 promotes mRNA vaccine-induced long-term immunity. J. Nanobiotechnol. 22, 716 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2769_CR407","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bbrc.2015.05.065","volume":"463","author":"C Yan","year":"2015","unstructured":"Yan, C. et al. Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity. Biochem. Biophys. Res. Commun. 463, 336\u2013343 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2769_CR408","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.biotechadv.2015.05.010","volume":"33","author":"AS Cordeiro","year":"2015","unstructured":"Cordeiro, A. S., Alonso, M. J. & de la Fuente, M. Nanoengineering of vaccines using natural polysaccharides. Biotechnol. Adv. 33, 1279\u20131293 (2015).","journal-title":"Biotechnol. Adv."},{"key":"2769_CR409","first-page":"129","volume":"43","author":"Y Guo","year":"2025","unstructured":"Guo, Y. et al. A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation. Bioact. Mater. 43, 129\u2013144 (2025).","journal-title":"Bioact. Mater."},{"key":"2769_CR410","doi-asserted-by":"publisher","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"2769_CR411","doi-asserted-by":"publisher","first-page":"102190","DOI":"10.1016\/j.coi.2022.102190","volume":"77","author":"B Geckin","year":"2022","unstructured":"Geckin, B., Konstantin Fohse, F., Dominguez-Andres, J. & Netea, M. G. Trained immunity: implications for vaccination. Curr. Opin. Immunol. 77, 102190 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"2769_CR412","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","volume":"57","author":"SM Nimjee","year":"2017","unstructured":"Nimjee, S. M., White, R. R., Becker, R. C. & Sullenger, B. A. Aptamers as therapeutics. Annu. Rev. Pharmacol. Toxicol. 57, 61\u201379 (2017).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2769_CR413","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu, Y., Lin, Q., Zhang, Z. & Zhang, L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm. Sin. B 10, 414\u2013433 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"2769_CR414","doi-asserted-by":"publisher","first-page":"12386","DOI":"10.1021\/acsnano.4c01518","volume":"18","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Metal-organic framework-based nanovaccine for relieving immunosuppressive tumors via hindering efferocytosis of macrophages and promoting pyroptosis and cuproptosis of cancer cells. ACS Nano 18, 12386\u201312400 (2024).","journal-title":"ACS Nano"},{"key":"2769_CR415","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner, S. M., Meier, J., Vincent, B. G. & Serody, J. S. B cell function in the tumor microenvironment. Annu. Rev. Immunol. 40, 169\u2013193 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"2769_CR416","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202411361","volume":"37","author":"W Yan","year":"2025","unstructured":"Yan, W. et al. Personalized multi-epitope nanovaccine unlocks B cell-mediated multiple pathways of antitumor immunity. Adv. Mater. 37, e2411361 (2025).","journal-title":"Adv. Mater."},{"key":"2769_CR417","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2025.01.078","volume":"380","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. Effective design of therapeutic nanovaccines based on tumor neoantigens. J. Control Release 380, 17\u201335 (2025).","journal-title":"J. Control Release"},{"key":"2769_CR418","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.trecan.2024.10.008","volume":"11","author":"A Rosenberg-Mogilevsky","year":"2025","unstructured":"Rosenberg-Mogilevsky, A., Siegfried, Z. & Karni, R. Generation of tumor neoantigens by RNA splicing perturbation. Trends Cancer 11, 12\u201324 (2025).","journal-title":"Trends Cancer"},{"key":"2769_CR419","doi-asserted-by":"publisher","first-page":"110640","DOI":"10.1016\/j.biopha.2020.110640","volume":"131","author":"P Xu","year":"2020","unstructured":"Xu, P. et al. Cancer neoantigen: boosting immunotherapy. Biomed. Pharmacother. 131, 110640 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2769_CR420","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1105420","volume":"14","author":"N Biswas","year":"2023","unstructured":"Biswas, N. et al. Designing neoantigen cancer vaccines, trials, and outcomes. Front. Immunol. 14, 1105420 (2023).","journal-title":"Front. Immunol."},{"key":"2769_CR421","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/2326-6066.CIR-20-0526","volume":"8","author":"EF Fritsch","year":"2020","unstructured":"Fritsch, E. F., Burkhardt, U. E., Hacohen, N. & Wu, C. J. Personal neoantigen cancer vaccines: a road not fully paved. Cancer Immunol. Res. 8, 1465\u20131469 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2769_CR422","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/s41588-025-02268-1","volume":"57","author":"Q Shi","year":"2025","unstructured":"Shi, Q. et al. Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation. Nat. Genet. 57, 2062\u20132073 (2025).","journal-title":"Nat. Genet."},{"key":"2769_CR423","doi-asserted-by":"publisher","first-page":"217752","DOI":"10.1016\/j.canlet.2025.217752","volume":"625","author":"H Li","year":"2025","unstructured":"Li, H. et al. Cancer mRNA vaccines: clinical application progress and challenges. Cancer Lett. 625, 217752 (2025).","journal-title":"Cancer Lett."},{"key":"2769_CR424","doi-asserted-by":"publisher","first-page":"1002313","DOI":"10.37349\/etat.2025.1002313","volume":"6","author":"MM Naffaa","year":"2025","unstructured":"Naffaa, M. M., Al-Ewaidat, O. A., Gogia, S. & Begiashvili, V. Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation. Explor. Target. Antitumor Ther. 6, 1002313 (2025).","journal-title":"Explor. Target. Antitumor Ther."},{"key":"2769_CR425","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."},{"key":"2769_CR426","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"2769_CR427","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg, A., Heine, A. & Brossart, P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer 10, 749\u2013769 (2024).","journal-title":"Trends Cancer"},{"key":"2769_CR428","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.bbi.2012.03.006","volume":"30(Suppl.)","author":"E Neeman","year":"2013","unstructured":"Neeman, E. & Ben-Eliyahu, S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav. Immun. 30(Suppl.), S32\u2013S40 (2013).","journal-title":"Brain Behav. Immun."},{"key":"2769_CR429","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-018-9896-8","volume":"35","author":"M Alieva","year":"2018","unstructured":"Alieva, M., van Rheenen, J. & Broekman, M. L. D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin. Exp. Metastasis 35, 319\u2013331 (2018).","journal-title":"Clin. Exp. Metastasis"},{"key":"2769_CR430","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.08.003","volume":"21-22","author":"S Blatter","year":"2015","unstructured":"Blatter, S. & Rottenberg, S. Minimal residual disease in cancer therapy-small things make all the difference. Drug Resist. Updat. 21-22, 1\u201310 (2015).","journal-title":"Drug Resist. Updat."},{"key":"2769_CR431","doi-asserted-by":"publisher","first-page":"672356","DOI":"10.3389\/fimmu.2021.672356","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front. Immunol. 12, 672356 (2021).","journal-title":"Front. Immunol."},{"key":"2769_CR432","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.trecan.2020.01.002","volume":"6","author":"HP Gerber","year":"2020","unstructured":"Gerber, H. P., Sibener, L. V., Lee, L. J. & Gee, M. H. Identification of antigenic targets. Trends Cancer 6, 299\u2013318 (2020).","journal-title":"Trends Cancer"},{"key":"2769_CR433","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3685","volume":"16","author":"R Takahashi","year":"2014","unstructured":"Takahashi, R. et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res. 16, R70 (2014).","journal-title":"Breast Cancer Res."},{"key":"2769_CR434","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.25976","volume":"122","author":"AC Gamboa","year":"2020","unstructured":"Gamboa, A. C. et al. Optimal timing and treatment strategy for pancreatic cancer. J. Surg. Oncol. 122, 457\u2013468 (2020).","journal-title":"J. Surg. Oncol."},{"key":"2769_CR435","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4161\/hv.23917","volume":"9","author":"C Ogi","year":"2013","unstructured":"Ogi, C. & Aruga, A. Clinical evaluation of therapeutic cancer vaccines. Hum. Vaccin. Immunother. 9, 1049\u20131057 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2769_CR436","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1039\/D0NH00267D","volume":"5","author":"Y Liao","year":"2020","unstructured":"Liao, Y. et al. Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications. Nanoscale Horiz. 5, 1293\u20131302 (2020).","journal-title":"Nanoscale Horiz."},{"key":"2769_CR437","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.medj.2025.100664","volume":"6","author":"G Zhao","year":"2025","unstructured":"Zhao, G., Wang, S. & Li, N. When UV1 cancer vaccine meets immune checkpoint blockade: Positive immune response but negative clinical outcome. Med 6, 100664 (2025).","journal-title":"Med"},{"key":"2769_CR438","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2022.12.007","volume":"181","author":"G Zhao","year":"2023","unstructured":"Zhao, G. et al. The clinical landscape of therapeutic cancer vaccines: the next breakthrough in cancer immunotherapy? Eur. J. Cancer 181, 38\u201341 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2769_CR439","first-page":"154","volume":"9","author":"MS Kohn","year":"2014","unstructured":"Kohn, M. S. et al. IBM\u2019s health analytics and clinical decision support. Yearb. Med. Inf. 9, 154\u2013162 (2014).","journal-title":"Yearb. Med. Inf."},{"key":"2769_CR440","doi-asserted-by":"publisher","first-page":"e1002829","DOI":"10.1371\/journal.pcbi.1002829","volume":"8","author":"JV Kringelum","year":"2012","unstructured":"Kringelum, J. V., Lundegaard, C., Lund, O. & Nielsen, M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput. Biol. 8, e1002829 (2012).","journal-title":"PLoS Comput. Biol."},{"key":"2769_CR441","doi-asserted-by":"publisher","first-page":"1322712","DOI":"10.3389\/fimmu.2024.1322712","volume":"15","author":"MH Hoie","year":"2024","unstructured":"Hoie, M. H. et al. DiscoTope-3.0: improved B-cell epitope prediction using inverse folding latent representations. Front. Immunol. 15, 1322712 (2024).","journal-title":"Front. Immunol."},{"key":"2769_CR442","doi-asserted-by":"publisher","first-page":"baz128","DOI":"10.1093\/database\/baz128","volume":"2019","author":"WJ Zhou","year":"2019","unstructured":"Zhou, W. J. et al. NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens. Database 2019, baz128 (2019).","journal-title":"Database"},{"key":"2769_CR443","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/2326-6066.CIR-19-0155","volume":"7","author":"CC Smith","year":"2019","unstructured":"Smith, C. C. et al. Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes. Cancer Immunol. Res. 7, 1591\u20131604 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2769_CR444","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cmpb.2017.10.011","volume":"153","author":"BA Moghram","year":"2018","unstructured":"Moghram, B. A., Nabil, E. & Badr, A. Ab-initio conformational epitope structure prediction using genetic algorithm and SVM for vaccine design. Comput. Methods Prog. Biomed. 153, 161\u2013170 (2018).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"2769_CR445","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-52","volume":"14","author":"P Oyarzun","year":"2013","unstructured":"Oyarzun, P., Ellis, J. J., Boden, M. & Kobe, B. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. BMC Bioinform. 14, 52 (2013).","journal-title":"BMC Bioinform."},{"key":"2769_CR446","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1501010","volume":"14","author":"S Imani","year":"2024","unstructured":"Imani, S. et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front. Cell Infect. Microbiol. 14, 1501010 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2769_CR447","doi-asserted-by":"crossref","unstructured":"Chan, A. et al. Designing lipid nanoparticles using a transformer-based neural network. Nat. Nanotechnol. 20, 1491\u20131501 (2025).","DOI":"10.1038\/s41565-025-01975-4"},{"key":"2769_CR448","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-316","volume":"8","author":"A Porollo","year":"2007","unstructured":"Porollo, A. & Meller, J. Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D. BMC Bioinform. 8, 316 (2007).","journal-title":"BMC Bioinform."},{"key":"2769_CR449","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/bmb.20966","volume":"44","author":"RE Rigsby","year":"2016","unstructured":"Rigsby, R. E. & Parker, A. B. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem. Mol. Biol. Educ. 44, 433\u2013437 (2016).","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"2769_CR450","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-021-00897-1","volume":"20","author":"J Towne","year":"2021","unstructured":"Towne, J., Carter, N. & Neivandt, D. J. COMSOL multiphysics(R) modelling of oxygen diffusion through a cellulose nanofibril conduit employed for peripheral nerve repair. Biomed. Eng. Online 20, 60 (2021).","journal-title":"Biomed. Eng. Online"},{"key":"2769_CR451","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","volume":"14","author":"Z Cheng","year":"2021","unstructured":"Cheng, Z., Li, M., Dey, R. & Chen, Y. Nanomaterials for cancer therapy: current progress and perspectives. J. Hematol. Oncol. 14, 85 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2769_CR452","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"2769_CR453","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/pharmaceutics11100534","volume":"11","author":"V Vijayan","year":"2019","unstructured":"Vijayan, V., Mohapatra, A., Uthaman, S. & Park, I. K. Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics 11, 534 (2019).","journal-title":"Pharmaceutics"},{"key":"2769_CR454","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103991","volume":"29","author":"D Chheda","year":"2024","unstructured":"Chheda, D. et al. Multifaceted therapeutic applications of biomimetic nanovaccines. Drug Discov. Today 29, 103991 (2024).","journal-title":"Drug Discov. Today"},{"key":"2769_CR455","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40580-024-00456-z","volume":"11","author":"SG Balwe","year":"2024","unstructured":"Balwe, S. G., Moon, D., Hong, M. & Song, J. M. Manganese oxide nanomaterials: bridging synthesis and therapeutic innovations for cancer treatment. Nano Converg. 11, 48 (2024).","journal-title":"Nano Converg."},{"key":"2769_CR456","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.coi.2012.12.008","volume":"25","author":"WA Li","year":"2013","unstructured":"Li, W. A. & Mooney, D. J. Materials based tumor immunotherapy vaccines. Curr. Opin. Immunol. 25, 238\u2013245 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"2769_CR457","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s13346-022-01241-3","volume":"13","author":"I Rana","year":"2023","unstructured":"Rana, I. et al. Nanocarriers for cancer nano-immunotherapy. Drug Deliv. Transl. Res. 13, 1936\u20131954 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"key":"2769_CR458","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu, Q. et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J. Hematol. Oncol. 17, 16 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2769_CR459","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1021\/acsnano.2c01252","volume":"16","author":"AE Nel","year":"2022","unstructured":"Nel, A. E., Mei, K. C., Liao, Y. P. & Liu, X. Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs. ACS Nano 16, 5184\u20135232 (2022).","journal-title":"ACS Nano"},{"key":"2769_CR460","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/acsabm.4c01797","volume":"8","author":"T Kanp","year":"2025","unstructured":"Kanp, T. et al. Exploring the potential of nanocarriers for cancer immunotherapy: insights into mechanism, nanocarriers, and regulatory perspectives. ACS Appl Bio Mater. 8, 108\u2013138 (2025).","journal-title":"ACS Appl Bio Mater."},{"key":"2769_CR461","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1080\/17435889.2024.2416377","volume":"19","author":"A Gharatape","year":"2024","unstructured":"Gharatape, A. et al. Recent advances in polymeric and lipid stimuli-responsive nanocarriers for cell-based cancer immunotherapy. Nanomedicine 19, 2655\u20132678 (2024).","journal-title":"Nanomedicine"},{"key":"2769_CR462","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.2147\/IJN.S454004","volume":"19","author":"MR Zhang","year":"2024","unstructured":"Zhang, M. R. et al. Advancements in stimulus-responsive co-delivery nanocarriers for enhanced cancer immunotherapy. Int. J. Nanomed. 19, 3387\u20133404 (2024).","journal-title":"Int. J. Nanomed."},{"key":"2769_CR463","doi-asserted-by":"publisher","first-page":"BSR20193220","DOI":"10.1042\/BSR20193220","volume":"39","author":"VU Warrier","year":"2019","unstructured":"Warrier, V. U. et al. Engineering anti-cancer nanovaccine based on antigen cross-presentation. Biosci. Rep. 39, BSR20193220 (2019).","journal-title":"Biosci. Rep."},{"key":"2769_CR464","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1039\/D3BM01746J","volume":"12","author":"E Yuba","year":"2024","unstructured":"Yuba, E. & Gupta, R. K. Preparation of glycopeptide-modified pH-sensitive liposomes for promoting antigen cross-presentation and induction of antigen-specific cellular immunity. Biomater. Sci. 12, 1490\u20131501 (2024).","journal-title":"Biomater. Sci."},{"key":"2769_CR465","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41401-020-0372-z","volume":"41","author":"F Yang","year":"2020","unstructured":"Yang, F. et al. Advanced biomaterials for cancer immunotherapy. Acta Pharmacol. Sin. 41, 911\u2013927 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"2769_CR466","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2174\/0929867324666170406111036","volume":"25","author":"L Liu","year":"2018","unstructured":"Liu, L., Li, X., Chen, L. & Zhang, X. Nanoscale functional biomaterials for cancer theranostics. Curr. Med. Chem. 25, 2987\u20133000 (2018).","journal-title":"Curr. Med. Chem."},{"key":"2769_CR467","doi-asserted-by":"publisher","first-page":"17332","DOI":"10.1002\/anie.202002780","volume":"59","author":"S Yan","year":"2020","unstructured":"Yan, S. et al. Improving cancer immunotherapy outcomes using biomaterials. Angew. Chem. Int. Ed. Engl. 59, 17332\u201317343 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2769_CR468","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1039\/D2CS00352J","volume":"52","author":"Z Pei","year":"2023","unstructured":"Pei, Z., Lei, H. & Cheng, L. Bioactive inorganic nanomaterials for cancer theranostics. Chem. Soc. Rev. 52, 2031\u20132081 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"2769_CR469","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02758-0","volume":"22","author":"Y Zhuo","year":"2024","unstructured":"Zhuo, Y. et al. Tailoring biomaterials for vaccine delivery. J. Nanobiotechnol. 22, 480 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2769_CR470","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002\u20131008 (2024).","journal-title":"Nat. Mater."},{"key":"2769_CR471","doi-asserted-by":"publisher","first-page":"e202318380","DOI":"10.1002\/anie.202318380","volume":"63","author":"S Dhoble","year":"2024","unstructured":"Dhoble, S., Wu, T. H. & Kenry Decoding nanomaterial-biosystem interactions through machine learning. Angew. Chem. Int. Ed. Engl. 63, e202318380 (2024).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2769_CR472","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1039\/D2CS00889K","volume":"52","author":"Q Fu","year":"2023","unstructured":"Fu, Q. et al. Bioorthogonal chemistry for prodrug activation in vivo. Chem. Soc. Rev. 52, 7737\u20137772 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"2769_CR473","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1039\/D1CS00451D","volume":"51","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. Metal-free bioorthogonal click chemistry in cancer theranostics. Chem. Soc. Rev. 51, 1336\u20131376 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"2769_CR474","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41578-021-00315-x","volume":"6","author":"J Wang","year":"2021","unstructured":"Wang, J., Li, Y. & Nie, G. Multifunctional biomolecule nanostructures for cancer therapy. Nat. Rev. Mater. 6, 766\u2013783 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"2769_CR475","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1039\/D2MH01358D","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Chen, J., Shi, L. & Ma, F. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. Mater. Horiz. 10, 361\u2013392 (2023).","journal-title":"Mater. Horiz."},{"key":"2769_CR476","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/ntno.27877","volume":"3","author":"A Ravindran Girija","year":"2019","unstructured":"Ravindran Girija, A. & Balasubramanian, S. Theragnostic potentials of core\/shell mesoporous silica nanostructures. Nanotheranostics 3, 1\u201340 (2019).","journal-title":"Nanotheranostics"},{"key":"2769_CR477","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1002\/anie.201908357","volume":"58","author":"G Yang","year":"2019","unstructured":"Yang, G. et al. Bioinspired core-shell nanoparticles for hydrophobic drug delivery. Angew. Chem. Int. Ed. Engl. 58, 14357\u201314364 (2019).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2769_CR478","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jconrel.2022.01.004","volume":"342","author":"Y Choi","year":"2022","unstructured":"Choi, Y. et al. Surface glycan targeting for cancer nano-immunotherapy. J. Control Release 342, 321\u2013336 (2022).","journal-title":"J. Control Release"},{"key":"2769_CR479","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.actbio.2023.02.026","volume":"161","author":"M Bao","year":"2023","unstructured":"Bao, M. et al. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease. Acta Biomater. 161, 250\u2013264 (2023).","journal-title":"Acta Biomater."},{"key":"2769_CR480","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1002\/anie.201403036","volume":"53","author":"T Sun","year":"2014","unstructured":"Sun, T. et al. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53, 12320\u201312364 (2014).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2769_CR481","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3070","volume":"37","author":"P Nasirmoghadas","year":"2021","unstructured":"Nasirmoghadas, P. et al. Nanoparticles in cancer immunotherapies: an innovative strategy. Biotechnol. Prog. 37, e3070 (2021).","journal-title":"Biotechnol. Prog."},{"key":"2769_CR482","doi-asserted-by":"publisher","first-page":"e1901081","DOI":"10.1002\/adma.201901081","volume":"32","author":"HJ Vaughan","year":"2020","unstructured":"Vaughan, H. J., Green, J. J. & Tzeng, S. Y. Cancer-targeting nanoparticles for combinatorial nucleic acid delivery. Adv. Mater. 32, e1901081 (2020).","journal-title":"Adv. Mater."},{"key":"2769_CR483","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s12094-023-03117-5","volume":"25","author":"J Li","year":"2023","unstructured":"Li, J. et al. Nanoparticles for cancer therapy: a review of influencing factors and evaluation methods for biosafety. Clin. Transl. Oncol. 25, 2043\u20132055 (2023).","journal-title":"Clin. Transl. Oncol."},{"key":"2769_CR484","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/1061186X.2023.2283838","volume":"31","author":"W Jiang","year":"2023","unstructured":"Jiang, W. et al. Recent advances in cancer cell bionic nanoparticles for tumour therapy. J. Drug Target. 31, 1065\u20131080 (2023).","journal-title":"J. Drug Target."},{"key":"2769_CR485","doi-asserted-by":"publisher","first-page":"112199","DOI":"10.1016\/j.msec.2021.112199","volume":"127","author":"G Kandasamy","year":"2021","unstructured":"Kandasamy, G. & Maity, D. Multifunctional theranostic nanoparticles for biomedical cancer treatments - a comprehensive review. Mater. Sci. Eng. C. Mater. Biol. Appl. 127, 112199 (2021).","journal-title":"Mater. Sci. Eng. C. Mater. Biol. Appl."},{"key":"2769_CR486","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s11427-019-9824-0","volume":"62","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Targeted nanoparticles for precise cancer therapy. Sci. China Life Sci. 62, 1392\u20131395 (2019).","journal-title":"Sci. China Life Sci."},{"key":"2769_CR487","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2019.11.002","volume":"69","author":"S Raj","year":"2021","unstructured":"Raj, S. et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin. Cancer Biol. 69, 166\u2013177 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"2769_CR488","first-page":"67","volume":"43","author":"SH Kim","year":"2025","unstructured":"Kim, S. H., Han, R. T., Han, H. S. & Kim, Y. M. Immune-modulative nano-gel-nano system for patient-favorable cancer therapy. Bioact. Mater. 43, 67\u201381 (2025).","journal-title":"Bioact. Mater."},{"key":"2769_CR489","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1039\/D5BM00284B","volume":"13","author":"ZL Wang","year":"2025","unstructured":"Wang, Z. L. et al. An injectable oncolytic hydrogel platform for in situ dendritic cell vaccination to boost antitumor immunity. Biomater. Sci. 13, 3016\u20133029 (2025).","journal-title":"Biomater. Sci."},{"key":"2769_CR490","first-page":"228","volume":"35","author":"X Li","year":"2024","unstructured":"Li, X. et al. Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold. Bioact. Mater. 35, 228\u2013241 (2024).","journal-title":"Bioact. Mater."},{"key":"2769_CR491","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Cancer vaccines: platforms and current progress. Mol. Biomed. 6, 3 (2025).","journal-title":"Mol. Biomed."},{"key":"2769_CR492","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/pharmaceutics17020216","volume":"17","author":"V Delgado-Almenta","year":"2025","unstructured":"Delgado-Almenta, V. et al. Cancer vaccines and beyond: the transformative role of nanotechnology in immunotherapy. Pharmaceutics 17, 216 (2025).","journal-title":"Pharmaceutics"},{"key":"2769_CR493","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.03.020","volume":"108","author":"P Bhardwaj","year":"2020","unstructured":"Bhardwaj, P. et al. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater. 108, 1\u201321 (2020).","journal-title":"Acta Biomater."},{"key":"2769_CR494","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202000110","volume":"9","author":"DM Valcourt","year":"2020","unstructured":"Valcourt, D. M. et al. Best practices for preclinical in vivo testing of cancer nanomedicines. Adv. Health. Mater. 9, e2000110 (2020).","journal-title":"Adv. Health. Mater."},{"key":"2769_CR495","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan, D. et al. Nanomedicine in cancer therapy. Signal Transduct. Target. Ther. 8, 293 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2769_CR496","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20\u201337 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2769_CR497","doi-asserted-by":"publisher","first-page":"125202","DOI":"10.1016\/j.ijpharm.2025.125202","volume":"671","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Navigating translational research in nanomedicine: a strategic guide to formulation and manufacturing. Int. J. Pharm. 671, 125202 (2025).","journal-title":"Int. J. Pharm."},{"key":"2769_CR498","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/pharmaceutics12111028","volume":"12","author":"A Perez-Lopez","year":"2020","unstructured":"Perez-Lopez, A., Martin-Sabroso, C., Torres-Suarez, A. I. & Aparicio-Blanco, J. Timeline of translational formulation technologies for cancer therapy: successes, failures, and lessons learned therefrom. Pharmaceutics 12, 1028 (2020).","journal-title":"Pharmaceutics"},{"key":"2769_CR499","doi-asserted-by":"publisher","first-page":"103677","DOI":"10.1016\/j.critrevonc.2022.103677","volume":"174","author":"MS Al-Zoubi","year":"2022","unstructured":"Al-Zoubi, M. S. & Al-Zoubi, R. M. Nanomedicine tactics in cancer treatment: Challenge and hope. Crit. Rev. Oncol. Hematol. 174, 103677 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2769_CR500","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nano.2015.08.006","volume":"12","author":"L Bregoli","year":"2016","unstructured":"Bregoli, L. et al. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine 12, 81\u2013103 (2016).","journal-title":"Nanomedicine"},{"key":"2769_CR501","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"2769_CR502","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano, L., Jordao, M. J. C. & Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11, 933\u2013959 (2021).","journal-title":"Cancer Discov."},{"key":"2769_CR503","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.trecan.2021.01.002","volume":"7","author":"K Thol","year":"2021","unstructured":"Thol, K. & McGranahan, N. Potential use of shared frameshift mutations in \u2018off-the-shelf\u2019 neoantigen vaccines. Trends Cancer 7, 175\u2013177 (2021).","journal-title":"Trends Cancer"},{"key":"2769_CR504","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06478-3","volume":"23","author":"A Mauriello","year":"2025","unstructured":"Mauriello, A. et al. Shared neoantigens\u2019 atlas for off-the-shelf cancer vaccine development. J. Transl. Med. 23, 558 (2025).","journal-title":"J. Transl. Med."},{"key":"2769_CR505","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1021\/acsnano.4c15765","volume":"19","author":"GC Zaccariotto","year":"2025","unstructured":"Zaccariotto, G. C. et al. Cancer nanovaccines: mechanisms, design principles, and clinical translation. ACS Nano 19, 16204\u201316223 (2025).","journal-title":"ACS Nano"},{"key":"2769_CR506","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"2769_CR507","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"2769_CR508","doi-asserted-by":"crossref","unstructured":"Saxena, M. et al. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematological malignancies in the adjuvant setting. Cancer Discov. 15, 930-947 (2025).","DOI":"10.1158\/2159-8290.CD-24-0934"},{"key":"2769_CR509","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"2769_CR510","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00262-020-02496-w","volume":"69","author":"QT Wang","year":"2020","unstructured":"Wang, Q. T. et al. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol. Immunother. 69, 1375\u20131387 (2020).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02769-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:01:17Z","timestamp":1784674877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02769-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":510,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02769-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.C. is a co-founder of and holds shares in Yantai Lannacheng Biotechnology Co., Ltd. Other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"285"}}